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1 Summary 
Several years ago, the definition of human blood dendritic cells (DCs) described by HLA-DR, 
CD4, CD11c and CD123 was extended by the discovery of blood dendritic cell antigens (BDCA) 
1-4. BDCA1+ (CD1c+) DCs, however, were not homogenous as they contained a substantial 
subpopulation carrying the monocyte marker CD14. BDCA1+CD14+ cells showed a marked 
phenotypic convergence with CD14+CD16- monocytes and it was unclear whether this 
population belonged to DCs or monocytes and what functions they had. 
This work describes for the first time BDCA1+CD14+ pro-inflammatory DCs (pro-iDCs) present 
in blood under steady state conditions. Although pro-iDCs shared phenotypic characteristics 
of CD14+CD16- monocytes, they expressed markers of activated DCs such as HLA-DR, CD40 
and CD54 but showed reduced expression of CXCR4, which is involved in monocyte 
hemostasis. This was in line with a strong DC function of ex vivo pro-iDCs as observed by the 
induction of allogeneic T cell proliferation, which is a hallmark of DCs. Pro-iDCs secreted high 
amounts of pro-inflammatory and polarizing cytokines already in the steady state, which was 
due to an enhanced susceptibility to reactive oxygen species and resultant autocrine IL-1β 
stimulation. Pro-iDC derived inflammatory cytokines matured conventional DCs (cDCs) and 
promoted T cell proliferation. Additionally, they secreted significant amounts of IL-12 and 
IL-23 and were superior in priming IFNγ+IL-17+ T cells when compared to BDCA1+CD14- DCs 
and CD14+CD16- monocytes. 
BDCA1+CD14+ cells resembling blood pro-iDCs were present in samples from patients suffering 
from psoriasis, dermatomyositosis and inflamed halo nevus, while lacking in healthy donor’s 
skin. The presence in inflamed but lack in healthy skin indicated that BDCA1+CD14+ cells were 
not tissue resident but recruited to sites of inflammation to promote immune responses. This 
is in line with mouse Ly6Chi monocytes, orthologs of human CD14+CD16- monocytes, that give 
rise to inflammatory DCs during inflammation. However, a detailed translation from the 
murine into the human system has not been succeeded, yet. In order to shed light on the 
developmental relationship between pro-iDCs and monocytes, pro-iDCs were compared to 
CD14+CD16- monocytes, cDCs and in vitro generated moDCs on a whole genome level. 
Transcriptome comparison between pro-iDCs and the other subsets indicated a monocytic 
origin, as numbers of genes differentially expressed were much smaller between pro-iDCs and 
monocytes than between pro-iDCs and other DC subsets. However, functional annotation 
analysis of genes upregulated in pro-iDC over monocytes revealed a DC specific signature, 
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whereas all monocyte specific genes were significantly higher expressed in monocytes 
compared to pro-iDCs. In addition, genes differentially regulated between pro-iDCs and 
monocytes were overall regulated in the same way by blood cDCs and in vitro generated 
moDCs, indicating an ongoing development of pro-iDCs from monocytes towards DCs. This 
developmental concept was supported as CD14+CD16- monocytes cultured under 
inflammatory conditions gained BDCA1 expression that correlated with a strong capacity to 
induce T cell proliferation.  
In summary, this work identifies a novel subset of pro-inflammatory DCs presumably of 
monocytic origin in peripheral blood present under steady state conditions. Pro-iDCs secreted 
vast amounts of pro-inflammatory cytokines and induced highly inflammatory TH17 cells. As 
pro-iDCs showed a high similarity with BDCA1+CD14+ cells found in situ only during 
inflammation and the recently described inflammatory DCs in inflamed tissues, pro-iDCs can 
be regarded as immediate precursors of inflammatory DCs. Thus, in respect of an obvious 
monocytic origin and a presumably inflammatory DC fate, pro-iDCs may constitute the first 
proof for moDC differentiation occurring in humans in vivo. 
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2 Zusammenfassung 
Vor einigen Jahren wurde die Definition von dendritischen Zellen (DZ) des Blutes neben den 
Markern HLA-DR, CD4, CD11c und CD123 mit der Entdeckung der Blut dendritischen Zell 
Antigene (BDCA) 1-4 ergänzt. BDCA1+ (CD1c+) DZ hingegen waren nicht homogen, da ein 
wesentlicher Anteil den monozytären Marker CD14 exprimierte. BDCA1+CD14+ Zellen zeigten 
eine deutliche phänotypische Übereinstimmung mit CD14+CD16- Monozyten und es war 
unklar, ob diese Subpopulation DZ oder Monozyten angehörten und ob sie mit individuellen 
Funktionen ausgestattet waren. 
Diese Arbeit beschreibt zum ersten Mal die Existenz von BDCA1+CD14+ pro-inflammatorischen 
DZ (pro-iDZ) im Blut unter homöostatischen Bedingungen. Obwohl pro-iDZ phänotypische 
Eigenschaften von CD14+CD16- Monozyten aufwiesen, exprimierten sie Marker aktivierter DZ 
wie HLA-DR, CD40 und CD54 und zeigten eine verringerte Expression des Markers CXCR4, der 
an der Homöostase von Monozyten beteiligt ist. Das stimmte mit DZ Funktionalität von ex vivo 
pro-iDZ überein: Sie induzierten eine starke allogene T Zell Proliferation, die ein Kennzeichen 
von DZ ist. Pro-iDZ sezernierten bereits im homöostatischen Zustand große Mengen an pro-
inflammatorischen und polarisierenden Zytokinen, die einer erhöhten Suszeptibilität 
gegenüber reaktiven Sauerstoff Spezies und einer daraus resultierenden autokrinen IL-1β 
Stimulation geschuldet waren. Die pro-inflammatorischen Zytokine, die von Pro-iDZ sezerniert 
wurden, maturierten konventionelle DZ (kDZ) und unterstützten T Zell Proliferation. Zusätzlich 
sezernierten sie erhebliche Mengen an IL-12 und IL-23 und waren bei der Polarisierung von 
IFNγ+IL-17+ T Zellen BDCA1+CD14- DZ und CD14+CD16- Monozyten überlegen.  
Pro-iDZ ähnliche BDCA1+CD14+ Zellen wurden nur in Hautproben von Patienten die an 
Psoriasis und Dermatomyositis litten oder ein entzündetes Halonävus trugen gefunden, 
während sie in Hautproben von gesunden Spendern fehlten. Die Anwesenheit in entzündeter 
und Abwesenheit in gesunder Haut deutete darauf hin, dass BDCA1+CD14+ Zellen nicht 
gewebsständig sind, sondern in entzündete Gewebe rekrutiert werden, um möglicherweise 
eine Immunreaktion zu fördern. Die Rekrutierung ist vergleichbar mit den zu CD14+CD16- 
Monozyten orthologen murinen Ly6Chi Monozyten, die unter entzündlichen Bedingungen zu 
inflammatorischen DZ differenzieren. Eine detaillierte Übertragung vom murinen in das 
humane System ist bisher jedoch noch nicht gelungen. Um Aufschluss über die 
entwicklungsbedingte Verwandtschaft zwischen pro-iDZ und Monozyten zu erhalten wurden 
in dieser Arbeit pro-iDZ mit CD14+CD16- Monozyten, kDZ des Blutes und in vitro generierte 
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aus Monozyten differenzierte DZ (moDZ) auf Genom-Ebene miteinander verglichen. Die 
Analyse des Transkriptoms zwischen pro-iDZ und den anderen DZ-Typen deutete auf einen 
monozytären Ursprung der pro-iDZ hin, da die Anzahl der differentiell exprimierten Gene 
zwischen pro-iDZ und Monozyten viel kleiner waren als zwischen pro-iDZ und den anderen 
DZ-Typen. Eine funktionelle Annotations-Analyse von Genen die in pro-iDZ höher reguliert 
waren als in Monozyten deckte eine DZ spezifische Gen-Signatur auf, wohingegen alle 
Monozyten-spezifischen Gene deutlich höher in Monozyten als in pro-iDZ reguliert waren. 
Zusätzlich waren die meisten der Gene in der gleichen Weise in den kDZ des Blutes und den 
in vitro generierten moDZ wie in den pro-iDZ reguliert, was auf eine beginnende Entwicklung 
der pro-iDZ von Monozyten zu DZ hindeutet. Diese in silico sich abzeichnende Entwicklung 
wurde zusätzlich unterstützt indem gezeigt werden konnte, dass CD14+CD16- Monozyten, die 
unter inflammatorischen Bedingungen kultiviert wurden, Expression des DZ Marker BDCA1 
erlangten, welche mit der Induktion von T Zell Proliferation korrelierte. 
Zusammengefasst identifiziert diese Arbeit pro-inflammatorische DZ unter homöostatischen 
Bedingungen im peripheren Blut mit wahrscheinlich monozytären Ursprung. Pro-iDZ 
sezernierten große Mengen an pro-inflammatorischen Zytokinen und induzierten 
hochentzündliche TH17 Zellen. Da pro-iDZ eine hohe Ähnlichkeit mit BDCA1+CD14+ Zellen, die 
nur in entzündeten Gewebe zu finden waren und starke Ähnlichkeit mit den erst kürzlich 
beschriebenen inflammatorischen DZ in entzündeten Geweben aufzeigten, können pro-iDZ 
als direkte Vorläuferzellen von inflammatorischen DZ angesehen werden. Ihr offensichtlicher 
Ursprung aus CD14+CD16- Monozyten deutet darauf hin, dass pro-iDZ das Bindeglied zwischen 
Monozyten und inflammatorischen DZ sind und somit den ersten in vivo Beweis für eine im 
Menschen stattfindende moDZ Differenzierung darstellen könnte. 
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3 Introduction 
3.1 Innate Immunity 
The immune system protects its host from pathogenic invaders including bacteria, viruses, 
parasites and fungi and eradicates host malignant cells. Pathogens that successfully 
penetrated physical and chemical barriers, e.g. skin or mucosa of the respiratory airway and 
gastrointestinal tracts, are confronted with a line of conserved, innate defense mechanisms. 
Antimicrobial proteins including defensins and the complement cascade1 inhibit extracellular 
pathogen growth2-4 and allow opsonization for uptake by phagocytic cells. Effector cells with 
high phagocytic activity including neutrophil granulocytes, monocytes and mast cells are 
attracted chemotactically to the site of inflammation where they become activated, take up 
and destroy pathogens or pathogen infected host cells5,6. Leukocytes sense conserved 
pathogen associated molecular patterns (PAMPs) and host danger associated molecular 
patterns (DAMPs) with a broad range of germ-line encoded pattern recognition receptors 
(PRRs), which mediate rapid cellular activation7,8. Activated leukocytes secrete vast amounts 
of soluble mediators including chemokines, interleukins (ILs), interferons (IFNs) and cytotoxic 
molecules that contribute to leukocyte attraction and activation or cause cell damage and 
thereby mediate pathogen clearance. Cells dying from infection or violence secrete nucleic 
and cytosolic constituents into the extracellular space where they act as DAMPs to alert its 
host9. Known DAMPs include nucleic acids10,11, chromatin associated proteins12, ATP13 and uric 
acid14. Recognition by specialized receptors can initiate and maintain sterile immune 
responses15. Common PAMPs are of bacterial, viral, fungal or parasitic origin and like DAMPs, 
they are recognized by vesicular and surface bound germ-line encoded Toll-like receptors 
(TLRs) 1-13 or cytosolic PRRs including DAI, RIG-I, MDA-5, PKR or AIM2, NOD1, NOD2. 
However, only 9 TLRs are known as functional receptors in humans16,17. The inflammasome 
constitutes another tightly regulated PRR complex. It controls the secretion of the highly 
inflammatory cytokines IL-1β and IL-18. The inflammasome consists of several components 
and is triggered by a plethora of stimuli leading to the activation of caspase-1 that cleaves 
immature pro-IL-1β and pro-IL-18 to functional cytokines18,19. Several inflammasomes are 
known and named after the receptor recognizing the PAMP or DAMP20,21. The AIM2 
inflammasome recognizes microbial or host aberrant dsDNA22,23, NLRP1 and NLRP4 
inflammasomes are activated by bacteria and its toxins24-27, whereas the most investigated 
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NLRP3 inflammasome is activated by crystallized endogenous molecules, microbial products 
and reactive oxygen species (ROS)28-34. ROS are thought to be a main trigger of NLRP3 
inflammasome activation and are induced in response to various stress signals35. Figure 1 
displays TLRs and IL-1R/IL-18R localization and signaling pathways and table 1 provides an 
overview of TLRs and their respective ligands. 
Figure 1 Localization and signaling pathways of IL-1R/IL-18R and TLRs 
Upon ligation with IL-1, IL-18 or respective Toll-like receptor (TLR) ligands, signaling is mediated via the TIR 
domains associated with each receptor. IL-1R/IL-18R and all TLRs signal via MyD88 adaptor protein except for 
TLR3 and in case of TLR2 and TLR4, TIR and MyD88 are bridged by TIRAP. TLR3 and TLR4 employ TRIF besides 
MyD88 signaling that leads over TBK1/TRAF3 and IKKe to the nuclear localization of IRF3 inducing transcription 
of IFN-β and IFN-inducible genes. MyD88 downstream events involve the phosphorylation of IRAK1/IRAK2 by 
IRAK4, allowing the association of IRAK1/2 with TRAF6. This complex activates the kinase TAK1 that promotes 
NF-kB (p50/p65) via IkB phosphorylation and AP-1 translocalization to the nucleus and subsequent transcription 
of pro-inflammatory cytokines. Besides MyD88 dependent IRAK4 signaling, vesicular TLR7, TLR8 and TLR9 
triggering leads to nuclear localization of IRF7 and promotes IFNα and IFN-inducible gene transcription. (Figure 
taken from Loiarro et al.36) 
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TLRs Ligands Synthetic ligand Pathogen 
TLR 1/2 Triacyl lipopeptides Pam3CSK4 Bacteria37,38 
TLR 2/6 Diacyl lipopeptides FSL-1 Mycoplasma 39 
TLR 3 Double stranded RNA Poly I:C Viruses40 
TLR 4 Lipopolysaccharide (LPS), 
bacterial HSP60 
LPS Gram-negative bacteria 41 
TLR 5 Flagellin Flagellin Bacteria42 
TLR 7 Single stranded RNA (ssRNA) R837, Loxoribin Viruses43 
TLR 8 ssRNA R848 Viruses43 
TLR 9 Unmethylated CpG-DNA 
oligonucleotides 
CpG-DNA Bacteria, viruses44 
TLR 10 Unknown Unknown Unknown45 
Table 1 TLRs and their respective natural and synthetic ligands with occurrence in pathogens 
Reviewed by Akira et al.46 
Soluble mediators do not only attract and modulate the function of innate immune cells, they 
also play a major role in lymphocyte recruitment and activation. They are usually secreted in 
response to PRR triggering. IFNα decreases the susceptibility of host cells to intracellular 
infections by the induction of antiviral gene expression47,48. Chemokines attract effector 
leukocytes to sites of inflammation and control trafficking of naïve lymphocytes within 
lymphoid organs49. For an organized immune response, leukocytes are able to communicate 
by the secretion and reception of interleukins and can modulate the cellular activation state50. 
IFNs activate natural killer cells (NK cells)51 to eradicate virus or bacteria infiltrated cells. NK 
cells lyse cells with an altered surface especially including reduced levels of human leukocyte 
antigen (HLA) molecule expression52,53. HLA class I molecules are important for the 
presentation of cell derived molecules to lymphocytes, which eradicate cells presenting non-
self molecules. Thus rendering MHC class I levels is a common escape mechanism of cellular 
pathogenic infection54,55 and a sign of malignant transformation56-58. Activated phagocytes as 
eosinophil granulocytes or monocytic cells are able to secrete nitric oxide (NO)59,60, reactive 
oxygen species (ROS)61-64 and cytotoxic proteins65 into the extracellular space to promote 
bacterial and parasitic killing66. However, pathogens are equipped with a number of 
mechanisms and a naturally high mutation rate to escape the recognition and eradication by 
innate immunity.  
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3.2 Adaptive immunity 
In contrast to the immediately activated innate immune system that is responding to a limited 
number of conserved structures, adaptive immunity requires more time for an educated, 
antigen specific reaction. Similar to innate immune defense mechanisms, adaptive immunity 
comprises both, a humoral response executed by antibody secreting B cells and a cellular 
response mediated by T cells that recognize cell bound antigens. In contrast to NK cells that 
detect the absence of HLA molecules, T cells specifically recognize host cell derived or 
endocytosed antigens loaded onto HLA molecules, allowing the determination between host 
and foreign1. Antigens presented in context of HLA molecules are proteins processed to short 
peptides. T cells use highly polymorphic and per cell uniform T cell receptors (TCRs)67,68 that 
enables the host to respond to a nearly unlimited number of antigens. TCRs are unlike PRRs 
not germ-line encoded and their recognition is not restricted to a limited number of 
structures. Instead, they are transcribed from randomly and locally rearranged parts of the 
genome, resulting in any number of TCRs with different specificities69. Clonal selection during 
development eradicates T cells that recognize host antigens and thereby favors detection of 
foreign, pathogen associated or host mutated antigens found in malignant cells70-72. Like TCRs, 
B cell receptors (BCRs), which are basically surface bound antibodies, are encoded by 
rearranged parts of the genome and B cells undergo clonal selection to avoid recognition of 
self, a cause of autoimmunity73. Cytotoxic CD8+ T lymphocytes (cTLs) are similar in function to 
NK cells, but eradicate target cells antigen specifically after recognition of peptides 
predominantly loaded onto HLA class I molecules74. By contrast, CD4+ helper T cells (TH cells) 
primarily detect peptides on HLA class II molecules75 and generally do not lyse the cells that 
present foreign antigen. Instead, TH cells activated by antigen recognition orchestrate complex 
immune responses at the site of inflammation involving the recruitment and activation of 
effector cells76. In order to meet the requirements to support the eradication of different 
types of pathogens, TH cell responses can be adapted by the polarization into different helper 
subsets dependent on the cytokine environment during their priming. Intracellular pathogens 
mainly induce IL-12 dependent TH1 responses77, whereas extracellular parasitic, bacterial and 
fungal infections cause TH2 and TH17 polarization, in a milieu containing IL-4 and IL-13 or IL-
1β, IL-6, IL-23 and TGF-β78-81, respectively. In order to strengthen the dominance of an 
established TH cell type response, cytokines also augment a specific polarization by inhibiting 
deviating TH cell polarizations. For example, TGF-β is thought to inhibit TH1 cell polarization 
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and therefore to favor TH17 differentiation82, whereas IL-12 induces TH1 cells and inhibits TH2 
polarization83. The defined set of cytokines secreted by polarized TH cells support specific 
immune functions that are required to eradicate distinct pathogens. IFNγ, mainly secreted by 
TH1 cells, promotes NK cell mediated lysis of cells infected with intracellular pathogens, 
increases phagocytic and lysosomal activity in macrophages to degrade ingested material and 
enhances the cellular antigen presentation machinery84. TH2 cells predominantly secrete IL-4, 
IL-5 and IL-13 and thereby activate granulocytes to secrete cytotoxic mediators85,86 that 
eradicate parasites present in the extracellular space. IL-17 produced by TH17 cells87 induces 
the secretion of inflammatory cytokines and chemokines from host cells to enhance 
inflammation and to attract effector cells including neutrophil granulocytes to the site of 
inflammation88 and thus supports fungal and bacterial clearance89,90. In addition, activated 
follicular helper T cells  (TFH cells) provide the necessary support for B cells to secrete antigen 
specific antibodies91 that play a major role in the neutralization of pathogens or their toxic 
metabolites present in the extracellular space1. Once the host has encountered a pathogen, it 
is “remembered” by the adaptive immune system for an immediate counteraction. A minor 
population of activated T and B cells undergoes memory cell differentiation and thereby 
establishes a long lasting antigen specific memory92. In contrast to TCRs consisting of an α and 
β chain93 and recognizing classical HLA molecules, lipid antigens on non-classical CD1 
molecules are recognized by T cells that are equipped with γ/δ TCRs (γ/δ T cells)94,95. In 
addition, γ/δ T cells are suspected to be a major producer of IL-17 during inflammation96. 
Finally, in order to initiate clonal activation and subsequent proliferation of antigen specific T 
and B cells, matured professional antigen presenting cells (APCs) are required. 
3.3 Dendritic cells as linkers of innate and adaptive immunity 
Dendritic cells (DCs) are professional APCs with continuous endocytotic activity in the 
immature state and high T cell stimulatory capacity after maturation. DCs were originally 
identified by Ralph Steinman and Zanvil Cohen in 197397. The heterogeneous DC populations 
originate from bone marrow CD34+ hematopoietic stem cells. While in mouse further 
development stages towards DC including a myeloid progenitor (MP), macrophage/DC 
precursor (MDP) and common DC precursors (CDP) are described, in humans a similar 
development is anticipated, however, human DC ontogenesis remains to be elucidated98,99. 
Introduction 
16 
Human DCs can be subdivided into Flt3L dependent BDCA2+CD123+ plasmacytoid DCs (pDCs) 
and conventional DCs (cDCs)100. cDCs are comprised of tissue resident and migratory DCs101. 
The cDC lineage is determined by the expression of transcription factors including IRF4102-105, 
BATF3106-108 and ZBTB46109,110. Whereas IRF4 and BATF3 are also expressed in lymphoid 
cells111,112, ZBTB46 has recently been described to be a master transcription factor for 
DCs109,110. Blood contains pDCs and myeloid cDCs, which consist of BDCA1+ DCs and 
BDCA3+CLEC9a+ DCs, whereas the skin contains epidermal CD207+ Langerhans cells and 
dermal CD14+ DCs and BDCA1+ DCs113. A pivotal task of DCs is the continuous uptake of 
extracellular material and its presentation to T cells. They are equipped with a number of cell 
surface bound receptors including scavenger receptors, c-type lectins (CLEC) and Fc receptors 
(FcRs) to sense and take up antigens114. The intracellular antigen degradation machinery is, 
unlike to other phagocytes, assigned for preserving small protein fragments, peptides 
consisting of up to 17 amino acids (aa) that are loaded onto HLA molecules allowing for TCR 
dependent T cell recognition115. In direct antigen presentation, class I HLA-molecules (HLA-A, 
B and C) bind intracellular derived peptides of 8-12aa in length116, whereas HLA class II 
molecules (HLA-DP, DQ and DR) are loaded with extracellular derived peptides with a length 
of 13-17aa117. The endocytosed material is strictly monitored for foreign PAMPs or host 
DAMPs by a broad range of PRRs118-120. As a consequence of PAMP recognition by respective 
TLRs or by IL-1 receptor (IL-1R) triggering, subsequent signaling as depicted in figure 1 leads 
to a complex signaling cascade finally resulting in the maturation of DCs121. In the course of 
maturation, DCs migrate to lymphatic tissues where they act as potent stimulators of antigen 
specific T cell responses122. Lymphatic tissues are highly organized structures that are 
continuously frequented by leukocytes to facilitate the encounter of cognate APCs and T 
cells123. In contrast to immature DCs, maturation includes a strong enhancement of the 
antigen presenting machinery activity and thereby forces a predominant loading of high 
amounts of HLA molecules with DAMP or PAMP associated antigens124,125. Since the entire T 
cell priming process including the localization and interaction with a cognate APC requires a 
persistent antigen presentation over a period of time, the half-life of surface HLA molecules 
on matured DCs is strongly increased126. A second signal besides TCR mediated antigen loaded 
HLA molecule recognition on the APC is required for T cell activation. It ensures an antigen 
specific T cell response focused on structures associated with an alert signal and thereby 
avoiding immune responses directed against self-antigens127,128. PAMP experienced DCs 
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upregulate the surface expression of T cell stimulatory and regulatory molecules including 
CD40, CD83129 and the B7-family members (CD80, CD86, CD273, CD274, CD275, CD276 and 
VTCN1)130 during maturation. Furthermore, stimulation of PRRs in DCs leads to the secretion 
of inflammatory, polarizing and regulatory cytokines including IL-1β, IL-6, TNFα, IL-12, IL-13, 
IL-23 and IL-10131-135. In the rare event of recognition of the antigen presented by matured 
DCs, the T cell undergoes rapid proliferation. DCs critically determine the type of TH cell 
polarization as these secrete certain sets of cytokines in response to various PAMPs. Activated 
T cells start to produce IL-2 and IL-2 receptor (CD25, CD122 and CD132 subunits) surface 
expression136,137 and thereby mediate their own clonal expansion138. Hence, CD25 
upregulation is regarded as a T cell activation marker. In the case antigen is recognized on 
immature DCs that have not undergone pathogen induced activation and thereby lack co-
stimulatory molecules, antigen specific peripheral T cell tolerance is induced139. Tolerance 
includes the induction of apoptosis and anergy or differentiation into regulatory T cells (Tregs), 
which dampen immune responses140. However, upon failure of tolerance induction, immune 
responses directed against host antigens can be established resulting in self-destructive 
autoimmunity. Thus, DCs critically determine the initiation and outcome of an immune 
response and several subsets have been ascribed specialized properties in this manner. A 
functional specialization can be suggested due to distinct expression PRR patterns in different 
DC subsets141,142. BDCA1+ DCs are equipped with many TLRs and respond to a wide range of 
PAMPs with maturation and unique cytokine expression143 that establishes a T cell polarizing 
and inflammatory environment, whereas pDCs are specialized in secreting vast amounts of 
antiviral type I IFN in response to TLR7 and TLR9 stimulation with nucleic acids144. BDCA3+ DCs 
are superior in antigen cross-presentation107,143,145, a process in that extracellular derived 
peptides are presented on HLA class I instead of class II molecules146. Cross-presenting DCs 
thereby provide the basis for cTL responses against intracellular pathogens147. Besides DCs 
differentiated from hematopoietic precursors at steady state, it is known that murine DCs can 
be derived from monocytes in vivo and in vitro. In humans it is verified that monocyte 
differentiate towards DC (moDC) in vitro and various protocols have been described. 
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3.4 Human monocyte derived DCs 
In vitro generated moDCs are widely used as a valuable tool and as a supplement for the rare 
and hard to isolate blood DCs, as moDCs are available in large numbers and can be generated 
with great plasticity148. A prototypic protocol used to induce human moDCs involves GM-CSF 
and IL-4 for differentiation from monocytes towards immature moDCs149. For moDC 
maturation, immature moDC were initially treated with monocyte cell culture derived 
supernatants termed monocyte-conditioned media (MCM)150. Later, Jonuleit et al.151 specified 
the cytokines contained in MCM required for moDC maturation as a cocktail of IL-1β, IL-6 and 
TNFα. He additionally applied PGE2 as an enhancer of the aforementioned cytokines. The 
resulting DCs gained inflammatory gene expression152 and a strong T cell proliferative 
capacity153,154. However, although PGE2 induces CCR7 expression, a receptor mediating 
homing to lymphatic tissues, it directs moDCs regulatory, as so treated cells attract and 
activate Tregs155 instead of naïve T cells156 and show decreased IL-12 and increased regulatory 
IL-10 secretion152,157. Instead, LPS and IFNγ are commonly used for inducing the secretion of 
inflammatory and TH1 polarizing cytokines and enhanced antigen presentation to CD4+ and 
CD8+ T cells158. Another maturation method using TNFα/CD40L favors TH2 responses and 
decreases the ability to activate cTL responses159. By contrast, IFNα accomplishes both, 
monocyte differentiation and maturation and enables so treated monocyte derived IFN-DCs 
to cross-present and prime antigen specific CD8+ T cell responses160. In addition to soluble 
mediators, cell-cell contact also drives the differentiation towards moDCs, as described for 
activated NK cells, macrophages and NKT cells161-163. Contact with CD8+ T cells leads to 
monocyte differentiation towards TNFα and iNOS producing DCs (Tip-DCs)164. Thus, 
monocytes differentiate into DCs with high plasticity including the expression of different sets 
of cytokines and surface markers, which depends on the presence of particular environmental 
factors. The high availability and plasticity of monocytes has made them targets with extensive 
use in cellular therapy approaches in malignant diseases. In vitro differentiated and tumor 
antigen loaded moDCs from monocytes were used to prime patients’ adaptive immune 
systems to eradicate neoplasms165-167. Despite the well-investigated human in vitro moDC 
model, a direct translation to the in vivo situation is commonly suspected but coherent 
evidence is missing. However, similar to moDCs generated in vitro, some studies report the 
existence of monocyte related DCs in vivo168-173. 
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3.5 Inflammatory DCs 
In contrast to naturally occurring DCs, inflammatory DCs are of monocytic origin and only 
found during inflammation174. In mice, it has been well established that inflammatory DCs 
differentiate Flt3L independently175-177 from Ly6ChiCD11b+CX3CR1low (Ly6Chi) monocytes 
under inflammatory conditions in vivo and in vitro. Ly6Chi monocytes traffic CCR2 dependently 
from the bone marrow (BM) to the blood stream178. During inflammation, they migrate to 
inflamed tissues and differentiate into CD11c expressing DCs179,180 where they become the 
dominant inflammatory cell type179-183. Subsequently they acquire the ability to migrate to 
draining lymph nodes and become the main population in the T cell areas173,184. They may act 
as potent antigen specific T cell stimulators of direct- and cross-presented antigens185. At the 
site of inflammation, some inflammatory DCs mainly act through innate defense mechanisms 
including TNFα/iNOS production and are therefore referred to as Tip-DCs. Tip-DCs are directly 
involved in parasitic clearance of Trypanosoma brucei186, Listeria monocytogenes187, Brucella 
melitensis188 in a TNFα and NO dependent way. Inflammatory DCs can also determine the 
polarization of TH cells depending on the immunological environment present during 
inflammatory DC differentiation. In HSV-2 and Listeria monocytogenes infection, 
inflammatory DCs restimulate and prime TH1 responses172,189, they induce TH2 responses 
mediated by house dust mite allergen190 and TH17 cells against the fungus Aspergillus 
fumigates182. In contrast to the involvement in host protective immune responses, 
inflammatory DCs have also been linked to experimental models of autoimmune diseases 
including allergic asthma175,190, rheumatoid arthritis191, colitis192,193, psoriasis194 and 
experimental autoimmune encephalomyelitis (EAE)195,196, an animal model for human 
multiple sclerosis.  
Until now, inflammatory DCs are identified by co-expression of several monocyte and DC 
specific markers and transcription factors as a single marker remains to be identified. As 
monocytes give also rise to macrophages197,198 and show phenotypic convergence with 
inflammatory DCs, analysis is complicated as a major challenge lies in the distinction of both 
cell types199. However, macrophages differ in their biologic functions from DCs. In contrast to 
inflammatory DCs, macrophages are mostly tissue resident and show a more 
anti-inflammatory role, which has been addressed to them by their strong ability to secrete 
IL-10199,200. They rather degrade ingested material and are limited in antigen presentation. In 
contrast to DCs, they show a low T cell stimulatory capacity and rarely migrate to lymphoid 
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organs201. Mouse inflammatory DCs express monocytic surface markers including CD115, 
F4/80 and CD11b as well as DC markers such as CD11c and high levels of MHC II, and CD40, 
CD86202 and CD64174,203. The expression of the transcription factor ZBTB46, which has recently 
been described to be specific for mouse and human DCs173, clearly affiliates them with DCs. 
To date, very limited data describes the phenotype and function of human inflammatory DCs. 
Similar to murine counterparts, the presence of human inflammatory DCs was found to be 
restricted to inflamed tissues and inflammation associated lymphatic organs. They shared 
hallmarks of activated DCs and like in vitro generated moDCs, inflammatory DCs appeared 
with varying phenotypes and functions.  
Inflammatory dendritic epidermal cells (IDECs) were first described in the skin of lesional 
atopic eczema, psoriasis vulgaris and atopic dermatitis, while lacking in non-lesional atopic 
eczema and healthy skin. They were defined by the expression of CD1a, CD11b, CD11c, 
FcεR1α, high levels of HLA-DR and CD36 and were distinct from skin resident Langerhans cells 
by the lack of Birbeck granules168,169. IDECs are thought to be related to TH1 and TH2 cell 
responses, because they were involved in the autoimmune skin disease atopic dermatitis, 
which is initiated and maintained by a TH2 and TH1 response, respectively204. Another type of 
inflammatory DCs, Tip-DCs, is present during inflammation and predominantly linked with the 
presence of TH1/TH17 cells. They were discovered in psoriatic lesions, an inflammatory 
autoimmune disease of the skin, by the expression of HLA-DR, CD11c and TRAIL and lack of 
BDCA1171,205,206. Their contribution to autoimmune inflammation was addressed to TNFα and 
NO secretion and priming of TH1 and TH17 immune responses171. Recently, another group 
identified inflammatory DCs in rheumatoid arthritic synovial fluids and tumor ascites and in 
the spleen from patients suffering from gastric cancer, while lacking in healthy donor’s tonsils, 
non-invaded lymph nodes from untreated breast cancer patients and in the spleen from 
pancreatic cancer patients. They were characterized by the co-expression of FcεR1α, the 
monocytic markers CD14 and CD11b, DC markers including BDCA1, CD206, high levels of HLA-
DR and a strong T cell proliferative capacity. Their inflammatory potential was underlined by 
the induction of TH17 responses mediated by the secretion of IL-1β, IL-6, IL-23 and TGF-β. In 
contrast to monocytes and macrophages, these inflammatory DCs expressed the DC specific 
transcription factor ZBTB46170.  
The authors of these studies suggested a monocytic origin of the respective inflammatory DCs. 
Their idea is supported as mouse Ly6Chi monocytes, orthologs of human CD14+CD16- 
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monocytes207, give rise to inflammatory DCs. However, the origin of inflammatory DCs 
remains to be identified. 
3.6 The aim of this study 
Mouse monocytes differentiate under pathogen encounter towards inflammatory DCs, which 
become numerically the main DC population in inflammatory diseases. They act as key players 
in protective as well as in self-destructive autoimmunity. As the beginning understanding of 
human inflammatory DCs in diseases seem to parallel murine observations, further 
understanding of human inflammatory DCs can offer valuable opportunities for intervention 
in a multitude of inflammatory diseases. 
In humans, three blood DC populations comprising pDCs, BDCA1+ DCs and BDCA3+ DCs are 
described. BDCA1+ DCs, however, are not homogenous, since a substantial population 
expresses the monocytic marker CD14. This BDCA1+CD14+ cell subset shares properties of 
both, monocytes and DCs and may constitute an intermediate development stage between 
both cell types. This study aims to characterize BDCA1+CD14+ cells on phenotypic, functional 
and whole genome level. 
 Material and Methods 
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4 Material and Methods 
4.1 Antibodies and staining 
Up  to  107  cells were  stained  in  CliniMACS  buffer  (Phosphate  Buffered  Saline  (PBS)/5mM 
Ethylenediaminetetraacetic acid (EDTA); Miltenyi Biotec) supplemented with 0.5%AB‐serum 
(Lonza) and  respective antibodies  in a  total volume of 110µl  for 10min at 4°C  in  the dark. 
Afterwards, cells were washed  in 1ml buffer/0.5% AB‐serum and resuspended  in 100‐300µl 
CliniMACS/0.5% AB‐serum  for  flow cytometric analysis. All antibodies used  including clone 
names are listed below: 
BDCA1‐PE  (AD5‐8E7),  BDCA1‐APC  (AD5‐8E7),  BDCA3‐APC  (AD5‐14H12),  BDCA3‐PE 
(AD5‐14H12),  CD3‐Vioblue  (BW264/56),  CD4‐FITC  (VIT4),  CD4‐Viogreen  (VIT4),  CD11b‐PE 
(M1/70.15.11.5),  CD11c‐PE  (MJ4‐27G12),  CD14‐FITC  (TÜK4),  CD16‐PE  (VEP13),  CD19‐APC 
(LT19),  CD25‐PE  (3G10),  CD32‐PE  (2E1),  CD36‐PE  (AC106),  CD40‐PE  (HB14),  CD45RA‐PE 
(T6D11),  CD45RO‐PE  (UCHL1),  CD64‐PE  (10.1.1),  CD68‐PE  (Y1/82A),  CD80‐PE  (2D10), 
CD83‐PE  (HB15), CD86‐PE  (FM95), HLA‐DR‐PE  (AC122), FcεR1α‐PE  (CRA1), CX3CR1‐PE  (2A9‐
1), CXCR4‐PE (12G5), CLA‐PE (HECA‐452), CD172a‐PE (REA144), CD163‐PE (GHI/61.1), CD206‐
PE (DCN228), CD209‐PE (DCN47.5), CD275‐PE (MIH12), CD276‐PE (FM276), SLAN‐PE (DD‐1), 
CLEC9a‐PE  (8F9),  IL‐6‐PE  (MQ2‐13A5),  IL‐10‐APC  (JES3‐9D7),  TNFα‐APC‐Vio770  (cA2), 
IFNγ‐FITC  (45‐15),  IL‐17‐APC  (CZ8‐23G1)    (all  Miltenyi  Biotec,  dilution:  1:11),  CD54‐APC 
(HA58) (dilution: 1:10), HLA‐ABC‐FITC (DX17, dilution: 1:50), CD1a‐PE (HI149, dilution: 1:10) 
(BD  Pharmingen),  CCR5  (45531,  20µg/ml),  CCR2‐PE  (48607)  (dilution  1:10,  both  R&D 
Systems), CD274‐PE (MIH1) (eBioscience) 
Mouse isotype controls included: IgG1‐PE (IS5‐21F5), IgG1‐APC (IS5‐21F5), IgG2a‐PE (S43.10), 
IgG2a‐APC (S43.10), IgG2b‐PE (IS6‐11E5.11) and IgG2b‐APC (IS6‐11E5.11) (all Miltenyi Biotec) 
Rat isotype controls included: IgG1‐APC (eBRG‐1) and IgG1‐PE (eBRG‐1; both eBioscience) 
Secondary antibodies: anti‐mouse IgG2ab‐PE (X‐57, dilution 1:11; Miltenyi Biotec) 
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4.2 Cell isolation 
4.2.1 PBMC Isolation 
Peripheral blood mononuclear cells (PBMCs) from healthy donors were isolated from buffy 
coats (Klinikum Dortmund) or from leukapheresis products (Klinikum Köln). Buffy coats were 
separated into three 50ml canonical tubes (BD Falcon) and filled with PBS/EDTA buffer to a 
total volume of 35ml. The cell suspension was carefully transferred to a new tube containing 
15ml Ficoll-Paque Plus or Pancoll (GE Healthcare, PAN Biotec, respectively) without disturbing 
the resulting overlaying phases. After centrifugation at 445g for 35min, the white leukocyte 
layer was removed into a new 50ml tube and filled with PBS/EDTA buffer to a total volume of 
50ml. The cells were centrifuged twice, subsequently at 300g and 200g for 15min and 
supernatants were replaced by 50ml CliniMACS buffer and with 10ml CliniMACS buffer/0.5% 
AB-serum, respectively. Leukapheresis products were initially separated into eight 50ml tubes 
and contents of two 50ml tubes were combined by each subsequent step. The cells were 
stored at 4°C over night and yielded 5x108 PBMCs from buffy coats and 4-10x109 PBMC from 
leukapheresis products on average. 
4.2.2 BDCA1+ DC isolation 
CD19 depleted BDCA1+ DCs were isolated from PBMC using the CD1c (BDCA-1)+ Dendritic Cell 
Isolation Kit according to manufacturer’s protocol. 
4.2.3 BDCA3+ DC isolation 
BDCA3+ DCs were isolated from PBMC using the CD141 (BDCA-3) Microbead Kit according to 
manufacturer’s protocol. 
4.2.4 pDC isolation 
pDCs were isolated from PBMC using the Plasmacytoid Dendritic Cell Isolation Kit II according 
to manufacturer’s protocol. 
4.2.5 Naïve CD4+ T cell isolation 
CD45RA+CD45RO-CD4+ T cells were isolated from PBMC using the Naïve CD4+ T Cell Isolation 
Kit II according to manufacturer’s protocol. 
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4.2.6 Monocyte isolation 
CD14+CD16-BDCA1- monocytes were isolated from PBMCs using the Monocyte Isolation Kit II 
according to manufacturer’s protocol. To deplete contaminating BDCA1+ cells, the first 
incubation with antibodies deviated from the protocol in that PBMCs were incubated with the 
monocyte-biotin-antibody cocktail additionally spiked with anti-BDCA1-biotin antibodies in a 
1:5 ratio. The resulting CD14+ cells were further purified using CD14-microbeads and 
subsequently separated using two LS-columns according to manufacturer’s protocol. 
4.2.7 Fluorescence Assisted Cell Sorting 
Magnetically purified BDCA1+CD19- cells as described in 4.2.2 were labeled with BDCA1-PE 
and CD14-FITC antibodies and stored in RPMI1640 (Miltenyi Biotec)/5% AB-serum pre-coated 
5ml polystyrene round-bottom tubes (BD Falcon) on ice. BDCA1+ cells were further flow sorted 
into BDCA1+CD14-, BDCA1+CD14int and BDCA1+CD14+ cells. Dead cells were discriminated by 
propidium iodide uptake and excluded by appropriate gating according to Figure 3. During 
sorting, cells were continuously kept at 4°C. Cell sorting was performed on a BD FACS Vantage 
SE at the Institute of Genetics (Cologne) and generally yielded purities of >98%.  
4.2.8 Flow cytometric analysis 
Cells were acquired on a MACSQuant analyzer and evaluated with MACSQuantify or FlowJo 
versions 10.0.5 and 10.0.6. 
4.2.9 Calculation of absolute BDCA1+ cell numbers from whole blood 
In order to obtain absolute BDCA1+CD14- DC and BDCA1+CD14+ pro-iDC cell numbers from 
healthy donor’s whole blood, blood average BDCA1 expressing cell numbers were obtained 
from literature208 and multiplied with the individual ratios of BDCA1+CD14- DCs / BDCA1+CD14+ 
pro-iDCs (Figure 4). Equivalent cell numbers from RA patients were obtained by the calculation 
of the arithmetic product of absolute cell numbers of BDCA1+CD19- cells from the unseperated 
cells and ratios of BDCA1+CD14- DCs / BDCA1+CD14+ pro-iDCs.  
4.3 Cell culture and treatment 
After isolation, dendritic cells and monocytes were cultured in RPMI1640 supplemented with 
5% AB-serum (Lonza), 1x Penicillin/Streptomycin and 2mM L-glutamin. For cultures containing 
T cells, medium was additionally supplemented with 1x non-essential amino acids and 1x 
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sodium-pyruvate (all Gibco). All cells were incubated in 96 flat bottom well plates at 37°C, 5% 
CO2 and 100% humidity. 
4.3.1 Cell treatment for microarray experiments 
BDCA1+CD14- DCs and BDCA1+CD14+ pro-iDCs were magnetically and subsequently flow 
sorted as described in 4.2.2 and 4.2.7. Monocytes were magnetically enriched as described 
4.2.6. Resulting CD14+CD16- monocytes were labeled with BDCA1-PE and CD14-FITC and flow 
sorted to obtain CD14+CD16-BDCA1- monocytes. 2x105 cells were lysed in RA1 lysis buffer 
(Macherey-Nagel) and stored at -70°C. In order to generate immature and mature monocyte-
derived DCs, monocytes were isolated from PBMC using CD14-microbeads and subsequent 
separation with LS and MS magnetic columns according to manufacturer’s protocol (Miltenyi 
Biotec). 107 monocytes were cultured in 10ml Mo-DC differentiation medium (Miltenyi Biotec) 
in T75 flasks (Becton, Dickinson). Medium was exchanged on day 4. On day 7, cells were 
washed and 5x105 cells were lysed in RA1 lysis buffer and stored at -70°C. The remaining cells 
were cultured for 3 more days in 10ml Mo-DC maturation medium (Miltenyi Biotec) in T75 
flasks. After a washing step, 5x105 cells were lysed as described above. RNA quality assessment 
based on 18S to 28S ribosomal subunit degradation was evaluated using the Agilent 2100 
Bioanalyzer expert software 3 (Agilent Technologies). Resulting RNA Integrity Numbers (RIN), 
based on a numbering system from 1 (mostly degraded) to 10 (perfectly intact), are depicted 
in table 2. Samples with a RIN >6 are regarded as acceptable.  
Sample 
No. 
BDCA1+CD14+ 
pro-iDC 
CD14+CD16-
BDCA1-
monocyte 
imoDC mmoDC BDCA1+CD14- 
DC 
BDCA3+CD14- 
DC 
1 9.0 7.3 9.6 9.3 9.0 8.0 
2 8.8 8.9 9.6 8.6 9.7 7.1 
3 9.1 8.5 9.7 8.5 8.6 7.4 
4 10.0 8.7 9.8 9.6 - - 
Table 2 RNA quality of samples included in microarray analysis 
Numbers indicate RNA Integrity Numbers (RIN) on a total scale from 1 (mostly degraded) to 10 (mostly intact) 
obtained from the Agilent 2100 Bioanalyzer expert software. (imoDC, immature monocyte derived dendritic cell; 
mmoDC, mature monocyte derived dendritic cell) 
4.3.2 Generation of APC supernatant and analysis of cytokine secretion 
5x104 BDCA1+CD14-CD19- DCs, BDCA1+CD14intCD19- cells, BDCA1+CD14+CD19- pro-iDCs, 
CD14+CD16-BDCA1- monocytes and BDCA3+CD14- DCs were cultured in 200µl medium (see 
4.3) for 24h in presence or absence of 10µg/ml Pam3CSK4 (Invivogen), 10µg/ml Poly I:C 
(Sigma), 100ng/ml LPS (Sigma), 100ng/ml Flagellin, 1µg/ml FSL-1, 5µg/ml R837, 5µg/ml R848 
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(all Invivogen), 5µg/ml CpG-B (Metabion). 1µg/ml double stranded DNA motif poly A:T was 
transfected with 0.5µg/ml Lipofectamin 2000 (both Invitrogen) according to manufacturer's 
protocol. To analyze the influence of erythrocytes on spontaneous cytokine secretion, 
autologous erythrocytes were co-cultured with BDCA1+CD14+ pro-iDCs at 50% hematocrit. 
Erythrocytes from density gradient centrifugation were washed three times in 1x PBS by 
centrifugation at 300g for 10min. To block the antioxidant system, erythrocytes were treated 
with 50mM aminotriazole (Sigma) and 0.4mM H2O2 (Sigma) at 37°C for 1h. After a subsequent 
washing step, the gluthatione peroxidase was inhibited by treatment with 0.2mM 
mercaptosuccinate (Sigma) at 37°C for 1h. To remove chemicals used during treatment, 
erythrocytes were washed thoroughly by 3 subsequent washing steps. To analyze the 
influence of reactive oxygen species on spontaneous cytokine secretion, BDCA1+CD14+ pro-
iDCs were treated with 20µM diphenyleneiodonium (DPI) and 20mM N-acetylcysteine (NAC, 
both Sigma). To analyze the influence of IL-1R signaling on spontaneous cytokine secretion, 
BDCA1+CD14+ pro-iDCs were treated with 4µg/ml IL-1β neutralizing antibody (BD Pharmingen, 
clone: AS10) and 10µg/ml IL-1R antagonist (IL-1RA, Miltenyi Biotec). As an isotype control, 
4µg/ml functional grade SIINFEKL antibody (Miltenyi Biotec, clone: 25-D1.16) was applied. Cell 
free supernatants were collected and kept at -70°C. Assessment of cytokine amounts was 
performed using cytokine bead arrays (Bender MedSystems and Miltenyi Biotec), IL-1β ELISA 
(Biolegend) and IL-23 ELISA (eBioscience) according to manufacturer’s instructions.  
4.3.3 Maturation of APCs using APC derived supernatants 
Cell supernatants of 24h cultured BDCA1+CD14-CD19- DCs, BDCA1+CD14+CD19- pro-iDCs and 
CD14+CD16-BDCA1- monocytes were collected as described in 4.3.2 and added in a 1:5 ratio 
to sorted BDCA1+CD14-CD19- DCs, BDCA3+CD14- DCs and CD14+CD16-BDCA1- monocytes. After 
24h, cells were stained for CD40-APC, CD80-APC, CD83-APC and CD86-FITC and analyzed using 
flow cytometry. 
4.3.4 Mixed leukocyte reaction 
Sorted BDCA1+CD14-CD19- DCs, BDCA1+CD14+CD19- pro-iDCs or CD14+CD16-BDCA1-
monocytes were serially diluted starting from 2.5x104 to 781 cells and stimulated with 5µg/ml 
R848 or left untreated. 5x104 naïve CD4+ T cells (for isolation see 4.2.5) were added to each 
well and cultured for 6 days. Cells were stained for CD3-Vioblue, CD4-FITC and CD3+CD4+ cell 
numbers were assessed by flow cytometry. 
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4.3.5 Anti-CD3/anti-CD28 bead supported cytokine mediated T cell proliferation 
Culture supernatants of R848 treated or unstimulated BDCA1+CD14- DCs and BDCA1+CD14+ 
pro-iDCs were generated as described in 4.3.2. Naïve CD4+ T cells were stained with the 
proliferation dye Violet Dye (Invitrogen) according to manufacturer’s protocol. 
5x104 Violet Dye+ T cells were stimulated with 2.5 x104 CD3/CD28 beads (Treg suppressor 
inspector, Miltenyi Biotec) that induced a sub-proliferative stimulation in presence or absence 
of 25µl supernatants resulting in 100µl total volume. After 84h of cultivation, proliferation was 
evaluated by flow cytometry. In some experiments, neutralizing antibodies recognizing IL-1β 
(BD Pharmingen, clone: AS10), IL-6 (clone: MQ2-13A5) and TNFα (clone: cA2; both Miltenyi 
Biotec) or respective isotype controls were used. Supernatants were incubated with 8µg/ml 
anti-IL-1β, 20µg/ml anti-IL-6 or 20µg/ml anti-TNFα at 37°C for 2h prior to addition to T cell 
cultures. The resulting concentrations for the culture period were 2µg/ml anti- IL-1β, 5µg/ml 
anti-IL-6 and 5µg/ml anti-TNFα. Isotype controls in the same order included, anti-mouse H- 
2Kb-SIINFEKL (mouse IgG1, clone: 25-D1.16), anti-mouse CLEC9a (rat IgG1, clone: 8F9) and a 
humanized anti-human IgG1 isotype antibody (all Miltenyi Biotec) and were applied in the 
same concentrations as the cytokine neutralizing antibodies. In some experiments, 
recombinant cytokines including 33ng/ml IL-1β, 100ng/ml IL-6 and 100ng/ml TNFα were used 
instead of APC derived supernatants. 
4.3.6 Intracellular cell staining 
105 magnetically enriched BDCA1+ cells or CD14+ monocytes were cultured for 6h in presence 
of absence of 10µg/ml Pam3CSK4 and for the final 4h cellular export was blocked by the 
presence of 0.4µg/ml Brefeldin A (Miltenyi Biotec) or analyzed for cytokine expression straight 
after isolation. For staining, cells were kept in approx. 20µl medium and a cocktail of BDCA1-
PE, CD14-FITC, IL-10-APC, TNFα-APC-Vio770 or BDCA1-APC, CD14-FITC, IL-6-PE or respective 
isotype controls were applied for 10min to the cells. Subsequently, incubation with 25µl 
InsideFix for 20min followed by 20µl 10x InsidePerm for 10min was applied. Cells were washed 
with 100µl 1x InsidePerm and centrifuged at 300g for 10min. Supernatants were removed and 
cells were resuspended in CliniMACS buffer/0.5% AB-Serum prior to analysis by flow 
cytometry. All steps were performed at RT and included initial 2 min shaking at 450rpm. All 
materials were obtained from Miltenyi Biotec. 
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4.3.7 T cell polarization assay 
Flow sorted BDCA1+CD14- DCs, BDCA1+CD14+ pro-iDCs (see 4.2.7) and CD14+CD16-BDCA1- 
monocytes (see 4.2.6) were cultured at a concentration of 5x104 cells in 100µl and stimulated 
with 10µg/ml Pam3CSK4, 10µg/ml Poly I:C, 100ng/ml LPS or 5µg/ml R848 or left unstimulated 
for 24h. 1x105 naïve CD4+ T cells were added to each well and cultured for 11 days. On days 4 
and 7, cells were splitted and supplemented with 4ng/ml IL-2 (Miltenyi Biotec). On day 9, cells 
were washed and kept deprived of IL-2. On day 11, cells were restimulated using 1µg/ml 
Ionomycin and 50ng/ml PMA (both Sigma) for 7h. During the last 5h, 2µg/ml Brefeldin A were 
added and cells were subsequently stained with CD3-Vioblue, CD4-Viogreen, IL-17-APC, IL-10-
PE and IFNγ-FITC following fixation and permebilization. Cells were acquired on a MACSQuant 
analyzer and analyzed using FlowJo 10.0.6. 
4.3.8 Statistical analysis 
Paired students’ t tests (with a 95% confidence interval), ANOVA with Bonferoni post-tests 
were performed using Prism 4.0 and 6.0 (GraphPad Software). P-values were defined as      *p 
< 0.05; **p < 0.01; and ***p < 0.001. 
4.3.9 May-Giemsa/Grünwald staining 
1x105 purified BDCA1+CD14-CD19- DCs, BDCA1+CD14+CD19- pro-iDCs and CD14+CD16-BDCA1-
monocytes (see 4.2.7) were immobilized on microscopy glass slides using cytospin technique. 
Briefly, 150µl cell suspension was applied to a reservoir that was mechanically adhered to the 
slide. After centrifugation at g for min, the reservoir was carefully removed and the slide was 
dried for 15min at RT. The slide was covered with 2.5ml May-Grünwald solution for 3min, 
carefully washed with dH2O, covered with 5ml Giemsa (Merck Millipore) solution for 15min 
and washed again. Slides were dried overnight at RT and images were taken on a Zeiss Axiostar 
plus microscope at 100x magnification using a Canon G7 camera. Image processing was 
performed using Graphic Converter software (Lemke Software GmbH, version 8.5.1). 
4.4 Patients 
Blood samples from 8 patients suffering from rheumatoid arthritis (RA) at a mean age of 51 
years ± 13.6 years (SD) were analyzed for frequencies of BDCA1+CD14- DCs and BDCA1+CD14+ 
pro-iDCs. Samples were analyzed as described in chapter 7.2.9. 7 individuals were seropositive 
for rheumatoid factor and/or anti-cytoplasmic antibodies (ACPA). The criteria of the American 
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College of Rheumatology (ACR) (revised in 2010) and the European League Against 
Rheumatism (EULAR)209,210 were fulfilled by all patients. Patients were negative for active 
tuberculosis and hepatitis and none had severe co-morbidities. Local ethics committees 
approved this study. The Department of Rheumatology and Clinical Immunology at the Charité 
Universitätmedizin Berlin randomly provided patients who agreed to these studies by a 
written informed consent.  
4.5 MELC 
The method to prepare images showing multiple parameters using MELC technology has been 
described by Eckhardt et al.211 In brief, a cryotome (Leica CM 3050S, Leica, Wetzlar, Germany) 
was used to prepare tissue sections of 5 µm. Sections were incubated in aceton (Carl Roth) for 
10 min at -20 °C and air-dried for 5 min. To avoid unspecific binding of antibodies, the sections 
were incubated in PBS (PAA, Pasching, Austria) for 5 min and subsequently in 5% NGS/PBS 
(Dako, Hamburg, Germany) for 30 min at RT. 24 fluorochrome-labeled antibodies and 
propidium iodide were used. Samples were analyzed on a Leica DM IRE2 using a 20x lens at a 
numerical aperature of 0.7 (Leica Microsystems, Wetzlar, Germany). A 900 x 900nm2 area 
corresponded to 1024 × 1024 pixels. To allow the acquisition of multiple parameters, samples 
were stained with fluorochrome labeled antibodies, washed, acquired on the microscope with 
a cooled CCD camera for image acquisition (Apogee KX4, Apogee Instruments) and bleached 
using the excitation wavelength in repetitive cycles. Automated image processing was 
performed with a software provided by the former company MelTec GmbH. Images were 
aligned to a preciseness of ±1 pixel and illumination faults were corrected using flat-field 
correction. 
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4.6 In silico methods 
4.6.1 RNA preparations and hybridization 
RNA from the DC and monocyte samples was extracted using NucleoSpin RNA II 
(Macherey-Nagel) according to manufacturer's protocol. For amplification, 25ng of each 
sample RNA were used and subsequently labeled with Cy3 using the Low Input Quick Amp 
Labeling Kit (Agilent Technologies) according to manufacturer's protocol. Labeled RNA 
samples were hybridized to an Agilent Whole Human Genome Oligo Microarray (8x60K; 
Agilent Technologies) for 17h at 65°C and washed with buffer 1 at RT and buffer 2 at 37°C for 
1min each and 30s with acetonitrile at RT. Fluorescent signal intensities were quantified 
employing the Microarray Scanner System (G2505C, Agilent Technologies) and resulting 
image files were processed using the Agilent Feature Extraction Software (FES 10.7.3.1). 
4.6.2 Microarray analysis 
Rosetta Resolver software (Rosetta, Inpharmatics, LLC.) was used to obtain raw intensity data 
from Feature Extraction output files. R/Bioconductor software suites (R version 2.13.1., 
http://www.R-project.org/212, http://www.bioconductor.org/213) were used for all 
calculations including background correction among intensity values (Figure 2A) and quantile 
normalization214 between arrays (Figure 2B). Signals were considered reliable if p≤0.01 
(Rosetta error model215).  Expression profiles were analyzed by correlation analysis on 
normalized log2 intensities and correlation coefficients were displayed in hierarchically 
clustered matrices using Euclidean distance and average linkage216. Statistical differences 
were evaluated using ANOVA- and Tukey post-hoc tests for multiple group comparisons on 
normalized log2 signal intensities, which were subsequently corrected for multiple testing 
according to Benjamini and Hochberg217. Genes were considered differentially expressed 
between groups of 2 cell populations if the median expression values differed ≥2 fold, p-values 
≤0.01 and Tukey p-values ≤0.01 between test and reference group. 
As prerequisite for considering a gene as differential expressed between 2 groups, only groups 
were allowed that had reliable signal intensities for all reporters in the group with higher 
expression (Rosetta p≤0.01). The data is publicly available via the NCBI Gene Expression 
Omnibus218 under the GEO Series accession number GSE54094. 
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4.6.3 Trend analysis 
Genes differentially expressed between BDCA1+CD14+ pro-iDCs and CD14+CD16-BDCA1- 
monocytes (see tables 3 and 4; p-value ≤ 0.01, Tukey p-value ≤0.01, and fold change ≤-2 (green 
circles) or ≥2 (red circles)) were considered for trend analysis. Correlation coefficients were 
obtained from pairwise comparisons of median log2 signal intensities from BDCA1+CD14+ pro-
iDCs against CD14+CD16-BDCA1- monocytes, BDCA1+CD14- DCs, BDCA3+CD14-  DCs, imoDCs 
and mmoDCs, respectively. 
4.6.4 Expression profiles for specific markers of dendritic cells and monocytes 
Genes with higher expression in BDCA1+CD14+ pro-iDCs over CD14+CD16- monocytes were 
analyzed for annotation enrichment using TreeRanker software (Miltenyi Biotec). After 
subtraction of the expected background, enriched terms were evaluated using Fisher's exact 
test and subsequently corrected for multiple testing217. Annotations were obtained from 
sources as described by Barral et al.219 These typically included GeneOntology (GO, 
www.geneontology.org), signaling pathway membership, sequence motifs, literature 
keywords and cell-specific marker genes. Genes selected according to significant enrichments 
in DC or monocyte specific markers were hierarchically clustered (Euclidean distance, 
complete linkage method220) and displayed in a heatmap image using TM4 suite221,220 (MeV 
4.8.1). 
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Figure 2 Boxplots of log2 transformed signal intensities 
Boxplots of raw (A) and quantile normalized (B) log2 intensities of indicated samples obtained from Human 
Genome Oligo Microarrays 8X60K (Agilent Technologies). The mark within the box indicates the median, the 
lower and upper boundaries represent the lower and upper quartile, respectively. The whiskers indicate 1.5 fold 
of the interquartile range and circles indicate outliers. (imoDC, immature monocyte derived dendritic cell; 
mmoDC, mature monocyte derived dendritic cell) 
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5 Results 
5.1 Phenotypic characterization of the BDCA1+CD14+ cell subset 
A decade ago, the expression of BDCA1 (CD1c) was described on CD3-, CD16-, CD19-, CD56-, 
CD11c+ and HLA-DR+ myeloid dendritic cells (DCs) in human peripheral blood222. However, 
BDCA1+ DCs were phenotypically not homogenous, as a substantial proportion of the cells 
expressed the monocyte marker CD14 at different levels, indicating similarities to monocytes. 
To date the CD14-expressing BDCA1+ cells were not further characterized so it remained 
unexplored whether these cells belong to the DC-lineage or rather resemble monocytes. 
Within the CD14+ fraction two different subsets could be identified, one expressing high levels 
of CD14 (Figure 3 gate C), termed BDCA1+CD14+ cells and an additional subset that expressed 
intermediate levels of CD14, termed BDCA1+CD14int, covering the expression range between 
the CD14- and CD14+ subset (Figure 3, gate B). In the present work the BDCA1+CD14+ cell 
subset is characterized. As a first step to shed light on the cellular affiliation, expression levels 
of various cell surface markers on BDCA1+CD14+ cells were compared to BDCA1+CD14- DCs 
and monocytes. Due to the low expression level of BDCA1 on the BDCA1+CD14+ cells a direct 
gating on BDCA1+CD14+ cells and BDCA1-CD14+ monocytes was not feasible. For this reason, 
BDCA1+ and BDCA1- cells were separated by magnetic cell sorting (MACS) prior to the flow 
cytometric analysis. To do so, a two-step strategy was chosen. In the first step human 
peripheral blood mononuclear cells (PBMCs) were depleted for B cells, which partly also 
express BDCA1, using CD19 conjugated magnetic beads (Miltenyi Biotec). In the second step 
the CD19- fraction was separated in a BDCA1+ fraction containing the CD14- (Figure 3, gate A) 
and CD14+ subsets (Figure 3, gate B + C) and a BDCA1- fraction containing CD14+CD16- 
monocytes (Figure 3, gate D). Peripheral blood BDCA1+ cells from the enriched fraction (the 
sum of cells contained in gates A + B + C) and magnetically purified CD14+CD16- monocytes 
(Figure 3, gate D) were then analyzed for the expression of further cell surface markers (Figure 
4). In experiments in which single BDCA1+ populations were required, CD19-BDCA1+ cells were 
flow sorted into BDCA1+CD14- DCs, BDCA1+CD14int and BDCA1+CD14+ cells (Figure 4, gates A, 
B and C). Expression levels of these markers were then compared between the BDCA1+ subsets 
and CD14+CD16- monocytes. The chemokine receptor CCR5, which is involved in tissue 
inflammation223, was highly expressed on BDCA1+CD14+ cells and CD14+CD16- monocytes 
compared to BDCA1+CD14- DCs whereas CLA, which mediates homing to the skin224, was 
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strongly upregulated on BDCA1+CD14- DCs. CCR2, CCR7 and CX3CR1 showed similar expression 
levels on all three subsets. In contrast, expression of CXCR4, a chemokine receptor that was 
reported to maintain the long-term CD4 and CD14 expression in monocytes/macrophages but 
not DCs225, clearly segregated BDCA1-expressing cells from CD14+CD16- monocytes. CXCR4 
was expressed at comparable levels on BDCA1+CD14+ cells and BDCA1+CD14- DCs and 
significantly lower when compared to CD14+CD16- monocytes. BDCA1+CD14+ cells showed the 
most activated phenotype as depicted by the expression of molecules involved in T cell 
stimulation: HLA-ABC, CD40, CD54 and CD86 were slightly higher regulated on BDCA1+CD14+ 
cells compared to BDCA1+CD14- DCs and CD14+CD16- monocytes. High expression levels of 
HLA-DR, which is a hallmark of dendritic cells226,227, was found 8-fold upregulated on BDCA1-
expressing cells when compared to CD14+CD16- monocytes. CD80, CD83, CD274, CD275 and 
CD276, also involved in DC-T cell interaction130,228-230 were almost not detectable on all subsets 
tested. Fc receptors including CD32 and CD64 were higher expressed on BDCA1+CD14+ cells 
and CD14+CD16- monocytes compared to BDCA1+CD14- DCs, whereas all subsets lacked CD16. 
In contrast, FcεR1α was regulated in an opposite way, being highest expressed on 
BDCA1+CD14- DCs. All cells were almost negative for the macrophage marker231 CD68, 
SLAN-DC marker232 SLAN, macrophage mannose receptor (CD206) and Langerhans cell 
marker233 CD1a. BDCA1+CD14+ cells expressed the highest levels of CD163, a marker 
predominantly expressed on monocytes and macrophages234. Several surface markers 
showed a gradual increase of expression levels from BDCA1+CD14- DCs to BDCA1+CD14+ cells 
and CD14+CD16- monocytes. Molecules including CD11b, the scavenger receptor CD36235 and 
the inhibitory receptor CD172a236,237 followed this pattern. As indicated in Figure 4, the BDCA1 
expressing CD14- and CD14+ cells might be present at different numbers. The comparison of 
the frequencies of BDCA1+CD14- DCs and BDCA1+CD14+ cells from whole blood in the BDCA1 
enriched PBMC fraction revealed a ratio of 1:3.8. In contrast, the percentages from perfused 
bone marrow cells, which were analyzed in the same way, showed an inverted ratio of 2.3:1 
(Figure 5). Taking together, except for few markers, the expression levels of markers on 
BDCA1+CD14+ cells was between the levels observed for BDCA1+CD14- DCs and CD14+CD16- 
monocytes. BDCA1+CD14+ cells thereby showed stronger phenotypic similarity to CD14+CD16- 
monocytes, however, expression levels of several markers were reminiscent of activated 
APCs, indicating that these cells may represent a developmental stage between monocytes 
and DCs. This was also reflected by morphological appearance of flow sorted BDCA1+CD14+ 
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Figure 5 Frequencies of BDCA1+CD14- DCs and BDCA1+CD14+ cells in the BDCA1 enriched fraction from human 
blood and perfused bone marrow cells 
The representative density plot shows magnetically enriched BDCA1+ cells from PBMC (A) and perfused bone 
marrow cells (B). Percentages of BDCA+CD14- DCs (CD14-) and BDCA1+CD14+ cells (CD14+) are indicated in the 
chart. One representative dot plot is shown. 
Figure 6 Light microcopy images of flow sorted May-Grünwald/Giemsa stained BDCA1+CD14- DC, BDCA1+CD14+ 
cell and BDCA1-CD14+BDCA1- monocyte from human blood 
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5.2 BDCA1+CD14+ cells produce high amounts of inflammatory cytokines 
By phenotypic analysis, BDCA1+CD14+ cells appeared to be very similar to monocytes (Figure 
4), however, some markers implied characteristics of activated professional APCs. In addition, 
elevated expression levels of BDCA1 pointed to an affiliation with BDCA1+ DCs. For further 
characterization beyond phenotype, levels of secreted cytokines from BDCA1+CD14+ cells 
were analyzed after TLR and cytosolic DNA PRR stimulation and compared to CD14+CD16- 
monocytes, BDCA1+CD14- DCs and BDCA3+CD14- DCs. Freshly isolated BDCA1+CD14+ cells 
diverged from the other APCs by the secretion of vast amounts of the inflammatory cytokines 
IL-1β, IL-6 and TNFα and significant levels of IL-10, IL-12 and IL-23 already in the absence of 
stimulation (Figure 7 A). None of the other ex vivo cell subsets analyzed produced cytokines 
without stimulation. To compare activated APCs in terms of cytokine secretion, a TLR8 ligand, 
R848 was applied to all subsets. TLR8 is a germ line encoded intracellular PRR sensing viral 
infection43 and expressed in BDCA1+CD14- DCs, BDCA3+CD14- DCs143, CD14+CD16- monocytes 
and moDCs238. After R848 stimulation, all cell types responded with cytokine production, 
dominated by IL-6 and TNFα, except for BDCA1+CD14+ cells, which principally secreted IL-1β. 
Compared to CD14+CD16- monocytes, BDCA1+CD14- DCs and BDCA3+CD14- DCs, BDCA1+CD14+ 
cells revealed a pro-inflammatory character by an over 10 fold higher inflammatory IL-1β 
secretion, indicating a stronger inflammasome activity. In addition, R848 stimulation lead to 
decreased levels of regulatory IL-10 when compared to untreated BDCA1+CD14+ cells (Figure 
7 B). BDCA1+CD14+ cells increased in secretion of TH1 and TH17 cell promoting cytokines IL-12 
and IL-23 and thus were comparable to cDCs rather than to CD14+CD16- monocytes, as these 
produced lower levels of IL-12 and no IL-23. BDCA3+CD14- DCs did not produce any IL-1β but 
were similar to BDCA1+CD14- DCs and BDCA1+CD14+ cells by the secretion of higher levels of 
IL-23. 
To distinguish cells by means of responsiveness to various pathogenic structures, a panel of 
TLR agonists was applied to all cell subsets and analyzed for cytokine secretion. Amounts of 
secreted cytokines of PRR triggered cells were set in relation to untreated cells. Whereas 
CD14+CD16- monocytes, BDCA1+CD14- DCs and BDCA3+CD14- DCs induced cytokine secretion 
following stimulation, BDCA1+CD14+ cells basically only altered the expression profile 
following Pam3CSK4 treatment by reduction in IL-10 and IL-23 levels and R848 stimulation as 
already described (Figure 8). 
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Except for Flagellin and CpG-B stimulation, any TLR stimulation resulted in a homogenous 
cytokine induction in monocytes for most cytokines, whereas IL-23 was not detected after FSL-
1 and R837 treatment. TNFα and IL-6 were highly induced, whereas IL-1β, IL-10 and IL-12 
induction was lower and at comparable levels. As monocytes are equipped with TLR5239 that 
recognizes Flagellin, the lack of cytokine induction was unexpected. Intracellular poly A:T 
delivery had no effect as treatment with the transfection reagent alone induced similar levels 
of cytokines. In line with a broad expression of TLRs in BDCA1+ DC143, all TLR agonists except 
for CpG-B led to induction of cytokines. In contrast to the inflammatory cytokine profile of 
BDCA1+CD14+ cells, the response from BDCA1+CD14- DCs was dominated by regulatory IL-10 
induction followed by TNFα, IL-6, IL-1β and IL-12, whereas IL-23 was only induced by poly I:C 
and R848 stimulation. However, BDCA1+CD14+ cells resembled rather BDCA1+CD14- DCs and 
BDCA3+CD14- DCs than CD14+CD16- monocytes, since cytokine secretion was principally 
induced by R848 stimulation, whereas CD14+CD16- monocytes responded to any TLR 
stimulation with homogenous levels of cytokines. Moreover, induction of the polarizing 
cytokines IL-12 and IL-23 was mainly induced by R848 in BDCA3+CD14- DCs and BDCA1+CD14+ 
cells, whereas IL-12 was reduced or not observable in both cell types after Pam3CSK4, when 
compared to most other stimulations. BDCA1+CD14- DCs were responsive to poly A:T 
stimulation, as this induced the highest levels of IL-23 besides TNFα, IL-1β, IL-6 and IL-10, 
implying the presence of functional cytoplasmatic dsDNA receptors. The amount of cytokines 
induced in BDCA3+CD14- DCs after stimulation with TLR agonists was the lowest when 
compared to the other APCs tested. TNFα and IL-6 were present after every treatment and 
surprisingly CpG-B induced significant levels of IL-6 and IL-23, which can be addressed to DNA 
receptors apart from TLR9, as BDCA3+CD14- DCs do not express TLR9143. In contrast to 
BDCA1+CD14- DCs, IL-23 was induced by Pam3CSK4 and R837 besides R848 in BDCA3+CD14- 
DCs. Latter induced the highest levels of cytokines and exclusively triggered IL-10 and IL-12 
secretion (Figure 8). By comparison, every subset could be ascribed a unique cytokine 
expression profile following TLR stimulation. However, despite the differences, BDCA1+CD14+ 
cells rather resembled BDCA1+CD14- DCs in responsiveness to TLR stimulation than 
monocytes, as latter showed very similar responses to basically all TLR agonists and former 
were principally triggered by R848 stimulation. However, a major difference lies in the types 
of secreted cytokines in between BDCA1+CD14+ cells and BDCA1+CD14- DCs, as BDCA1+CD14+ 
cells predominantly secreted inflammatory cytokines whereas BDCA1+CD14- DCs showed high 
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induction of IL-10. BDCA3+CD14- DCs generally responded with low levels of cytokines but 
were like BDCA1+CD14+ cells and BDCA1+CD14- DCs and unlike CD14+CD16- monocytes most 
responsive to R848 stimulation. However, the high secretion of cytokines from untreated 
BDCA1+CD14+ cells and low responsiveness to TLR ligands was surprising and indicated an 
already TLR like activation, which required further investigation. 
Figure 7 Ex vivo BDCA1+CD14+ cells secrete high amounts of inflammatory and polarizing cytokines 
Flow sorted BDCA1+CD14- DCs, BDCA1+CD14+ cells, CD14+CD16-BDCA1- monocytes and BDCA3+CD14- DCs were 
cultured for 24h in the absence (A) or presence (B) of R848. Cell free supernatants were harvested and analyzed 
for cytokine levels of IL-1β, IL-6, TNFα, IL-10, IL-12 and IL-23 by cytometric bead array (CBA) and enzyme-linked 
immunosorbent assay (ELISA) (n=3). Error bars represent SEM. 
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Figure 8 Cytokine secretion profiles of pattern recognition receptor (PRR) stimulated APCs 
Flow sorted BDCA1+CD14- DCs, BDCA1+CD14+ cells, CD14+CD16- monocytes and BDCA3+CD14- DCs were cultured 
in the presence of different TLR agonists and cytosolic delivered poly A:T sequence dsDNA using Lipofectamin 
2000 (pA:T + LF2000). After 24h of stimulation, cell free supernatants were collected and cytokine levels of IL-1β, 
IL-6, TNFα, IL-10, IL-12 and IL-23 were analyzed by cytometric bead array (CBA) and enzyme-linked 
immunosorbent assay (ELISA). Shown is the percent change of secreted cytokines of stimulated cells relative to 
cells cultured in medium alone (n=3).  
1
10
100
1000
10000
100000
1000000
1
10
100
1000
10000
100000
1000000
1
10
100
1000
10000
100000
1000000
1
10
100
1000
10000
100000
1000000
BDCA1+CD14+ cell 
BDCA1+CD14- DC 
CD14+CD16- Monocyte 
BDCA3+CD14- DC 
%
 In
du
ct
io
n 
Fl
ag
el
lin
 
LF
20
00
 +
 p
A
:T
 
Pa
m
3C
SK
4 
Po
ly
 I:
C 
LP
S 
FS
L-
1 
R8
37
 
R8
48
 
Cp
G
-B
 
LF
20
00
 
pA
:T
 
TNFα
IL-1b
IL-6
IL-10
IL-12p70
IL-23
%
 In
du
ct
io
n 
%
 In
du
ct
io
n 
%
 In
du
ct
io
n 
Results 
42 
Figure 9 Magnetically enriched BDCA1+CD19- cells do not secrete cytokines without stimulation 
Magnetically enriched BDCA1+ cells from CD19 depleted PBMCs were cultured in the presence or absence of 
indicated antibodies or Pam3CSK4 (n=5). After 24h, cell free supernatants were collected and cytokine levels of 
IL-6, TNFα, IL-10 and GM-CSF were analyzed by cytometric bead array (CBA). Error bars represent SEM. 
5.3 Spontaneous cytokine release is due to ROS and appears after flow sorting 
The spontaneous release of cytokines from flow sorted BDCA1+CD14+ cells was a surprising 
observation and as this was not reported from any other primary blood cell type, the 
underlying mechanisms were investigated. After magnetic isolation, the ex vivo BDCA1+ cell 
fraction including BDCA1+CD14- DCs, BDCA1+CD14int cells and BDCA1+CD14+ cells did not 
produce significant amounts of cytokines (Figure 9) as it was the case for flow sorted 
BDCA1+CD14+ cells (Figure 7). In addition, none of the antibodies used for flow sorting of 
BDCA1+CD14+ cells was able to trigger cytokine secretion. The spontaneous release of 
cytokines after flow sorting from BDCA1+CD14+ cells was unique, as both flow sorted, 
BDCA1+CD14- DCs and BDCA1+CD14int cells did not release significant amounts of cytokines 
without appropriate stimulation (Figure 7 and 10). To address the question, whether the high 
amounts of cytokines from BDCA1+CD14+ cells were due to the release of pre-synthesized 
cytokines by cell necrosis occurring during cell culture, freshly isolated BDCA1+CD14- DCs, 
BDCA1+CD14+ cells and CD14+CD16- monocytes were stained intracellularly for TNFα and IL-6 
(Figure 11).  
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compared to BDCA1+CD14- DCs and CD14+CD16-BDCA1- monocytes after 6h of culture in the 
presence of R848. (Figure 11 B). In addition, as mRNA levels of all tested cytokines were 
comparable in BDCA1+CD14- DCs, BDCA1+CD14+ cells, CD14+CD16- monocytes and 
BDCA3+CD14- DCs, levels of transcripts in BDCA1+CD14+ cells could not explain the rapid and 
strong cytokine secretion (Figure 12).  
Figure 12 mRNA levels of selected cytokines from non-cultured BDCA1+CD14- DCs, BDCA1+CD14+ cells, 
CD14+CD16-BDCA1- monocytes and BDCA3+CD14- DCs  
Relative gene expression levels of indicated cytokines were obtained from normalized whole genome microarray 
experiments as described in detail in the material and methods section. Samples included flow sorted 
BDCA1+CD14- DCs, BDCA3+CD14- DCs (n=3), CD14+CD16-BDCA1- monocytes, BDCA1+CD14+ cells and in vitro 
generated immature and mature monocyte derived DCs (imoDC, mmoDC) (n=4). Error bars represent SEM. 
BDCA1+CD14+ cells only secreted cytokines in the absence of PRR stimulation after flow sorting 
(Figure 7). As another candidate mechanism for the spontaneous release of cytokines, the role 
of reactive oxygen species (ROS) in cytokine production was determined. ROS are able to 
induce cytokine production240,241 and flow sorting increases cellular susceptibility to ROS242. 
Thus spontaneous cytokine secretion of flow sorted BDCA1+CD14+ cells could be due to an 
enhanced susceptibility to ROS induced cytokine secretion. The involvement of ROS appeared 
feasible since BDCA1+CD14+ cells produced the highest amounts of ROS compared to 
BDCA1+CD14- DCs and CD14+CD16- monocytes within 6h cell culture (Figure 13).  
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Figure 14 Spontaneous release of cytokines from BDCA1+CD14+ cells is caused by reactive oxygen species (ROS) 
Flow sorted BDCA1+CD14+ cells were cultured in the presence or absence of R848 and pharmacological ROS 
inhibitors diphenylene-iodide (DPI) and N-acetylcysteine (NAC). As DPI was dissolved in DMSO, it was included 
as a control. After 24h, cell free culture supernatants were collected and cytokine levels of IL-6, TNFα, IL-10, GM-
CSF and IL-1β were analyzed by cytometric bead array (CBA) and enzyme-linked immunosorbent assay (ELISA), 
respectively. Percent changes normalized to untreated cells are shown (n=5). Error bars represent SEM. 
IL-1β was reported to promote cytokine secretion in mononuclear cells250,251. Thus, a possible 
role for IL-1β induced cytokine secretion was determined for BDCA1+CD14+ cells. After IL-1R 
blocking using IL-1R antagonist (IL-1RA) flow sorted BDCA1+CD14+ cells secreted reduced 
amounts of IL-6, TNFα, GM-CSF and IL-10 (Figure 15).  
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Figure 15 Inflammatory cytokines and IL-10 secretion by BDCA1+CD14+ cells is in part induced by IL-1β  
Flow sorted BDCA1+CD14+ cells were cultured in the presence or absence of IL-1 receptor antagonist (IL-1RA), 
neutralizing IL-1β antibody (aIL-1β) or a respective isotype control. After 24h, cell free supernatants were 
collected and cytokine levels were analyzed by cytometric bead array (CBA). Percent changes normalized to 
untreated cells are shown (n=5). Error bars represent SEM. 
When IL-1β neutralizing antibodies were additionally applied, levels of cytokines further 
declined. However, cytokine secretion was not completely abolished in the presence of IL-1RA 
or neutralizing IL-1β antibody.  
As BDCA1+CD14+ cells appear to be prone to ROS generation or susceptible for ROS during 
cellular stress and ROS mediate the spontaneous release of cytokines, an inhibitory 
mechanism in blood is likely to exist, as TNFα secretion in blood can induce a health 
threatening septic shock252. Cytokine secretion in response to PAMP in SLAN DCs is inhibited 
by the presence of erythrocytes, mediated by CD47 binding to CD172a on DCs236. In order to 
check for a similar inhibitory role, pro-iDCs were co-cultured with erythrocytes in the presence 
or absence of TLR ligands. However, erythrocytes rendered the CD172a expressing (Figure 4) 
BDCA1+CD14+ cells regulatory by enhanced IL-10 secretion but inflammatory cytokines were 
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not affected throughout all treatments (Figure 16). Even the decrease of IL-10 after R848 
stimulation (Figure 7) was subverted in the presence of erythrocytes. 
Thus, these data indicate an enhanced capacity for ROS generation and increased ROS 
susceptibility of BDCA1+CD14+ cells, which became effective here after flow sorting leading to 
inflammatory cytokine secretion in vitro.  
Figure 16 Erythrocytes increase IL-10 production in BDCA1+CD14+ cells in vitro 
Flow sorted BDCA1+CD14+ cells were cultured in the presence or absence of autologous, antioxidant system and 
gluthatione peroxidase inactivated erythrocytes (Ery) in 1000 fold excess. After 24h, cell free supernatants were 
collected and indicated cytokine levels were analyzed by cytometric bead array (CBA) (n=5). Error bars represent 
SEM. 
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5.4 BDCA1+CD14+ cells induce TH17 cell responses 
The cytokines secreted by BDCA1+CD14+ cells including IL-1β, IL-6, IL-23 and IL-12 were 
described to prime and maintain TH17 and TH1 cells78,79,81. In order to elucidate their 
polarization capacity, BDCA1+CD14+ cells were co-cultured with allogeneic naïve CD4+ T cells 
and compared to BDCA1+CD14- DCs and CD14+CD16- monocytes (Figure 17). According to the 
spontaneous release of inflammatory and polarizing cytokines, already unstimulated 
BDCA1+CD14+ cells were effective in priming TH17 cells. In line with enhanced IL-1β secretion 
after LPS and R848 stimulation (Figure 4), the percentage of IL-17 producing T cells induced 
by BDCA1+CD14+ cells slightly increased (Figure 17 A, B). In contrast, BDCA1+CD14- DCs and 
CD14+CD16- monocytes required TLR mediated stimulation for TH17 induction. However, 
BDCA1+CD14+ cells were superior in priming TH17 cells, since frequencies of IL-17 producing T 
cells were generally lower with BDCA1+CD14- DCs and CD14+CD16- monocytes (Figure 17 B). 
BDCA1+CD14- DCs and CD14+CD16- monocytes were similar in TH17 cell induction throughout 
all stimulations. All tested subsets induced high frequencies of IFNγ+ T cells even in the 
absence of stimulation (Figure 17 C). CD14+CD16- monocytes predominantly induced 
regulatory IL-10 producing T cells and most significantly after stimulation with TLR agonists 
(Figure 18 D). According to the induction of high frequencies of TH17 cells, BDCA1+CD14+ cells 
were superior in inducing IL-17+ T cells co-producing IFNγ when compared to BDCA1+CD14- 
DCs and CD14+CD16- monocytes (Figure 17 E), which was reported be to due to IL-1β253 and is 
in line with their superior IL-1β secretion. Among several APCs, the highly inflammatory 
IFNγ+IL-17+ T cells were reported to be primarily induced by human inflammatory DCs170 and 
associated with several autoimmune diseases171,254-256. CD14+CD16- monocytes were superior 
in inducing IL-10+ T cells co-producing IFNγ (Figure 17 F), which were associated with 
protection against collateral immune damage but are also involved in chronic infection due to 
the failure of pathogen elimination257. Induction of IL-17+IL-10+ T cells was not observed from 
any subset (Figure 17 G). Although highly similar in phenotype, BDCA1+CD14+ cells and 
CD14+CD16- monocytes differ in function: BDCA1+CD14+ cells on the one hand are highly 
inflammatory cells evinced by their superior capacity to induce IL-17+ T cells whereas 
CD14+CD16- monocytes on the other hand are rather regulatory by mainly inducing IL-10+ T 
cells. 
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5.5 BDCA1+CD14+ cells functionally resemble DCs 
To further distinguish BDCA1+CD14+ cells on functional level from either monocytes or DCs, 
BDCA1+CD14- DCs, BDCA1+CD14+ cells and CD14+CD16- monocytes were compared for T cell 
stimulatory capacity. Therefore, expression levels of molecules involved in T cell activation130 
including CD40, CD80, CD83, CD86, HLA-ABC and HLA-DR were analyzed after treatment with 
a panel of TLR agonists and intracellularly delivered dsDNA (Figure 18). BDCA1+CD14- DCs and 
BDCA1+CD14+ cells increased expression levels of CD40, CD80 and HLA-ABC the most after 
treatment with Poly I:C, LPS and R848. CD83 was upregulated by all TLR agonists except for 
CpG-B in BDCA1+CD14- DCs. CD83 expression levels on BDCA1+CD14+ cells followed the same 
pattern although with reduced intensity. While CD86 was mainly induced after Poly I:C, LPS 
and R837 on BDCA1+CD14- DCs, induction on BDCA1+CD14+ cells was restricted to LPS 
stimulation. HLA-DR expression was unaltered throughout all stimulations in all cells types. 
Intracellular dsDNA stimulation enhanced expression of co-stimulatory molecules and HLA-
ABC the most in BDCA1+CD14+ cells and BDCA1+CD14- DCs when compared to CD14+CD16- 
monocytes. Thus, BDCA1+CD14+ cells and BDCA1+CD14- DCs similarly share the ability to 
mature upon stimulation with TLR agonists, whereas CD14+CD16- monocytes remain 
immature.  
Since ex vivo BDCA1+CD14+ cells showed an enhanced expression of the T cell stimulatory 
molecules HLA-DR, CD40, CD54 and CD86 (Figure 4) their function was tested in an allogeneic 
T cell co-culture (Figure 19). Compared to BDCA1+CD14- DCs and CD14+CD16- monocytes, 
BDCA1+CD14+ cells induced the strongest T cell proliferation, which is a hallmark of dendritic 
cells258. However, after treatment with R848, BDCA1+CD14- DCs were superior compared to 
BDCA1+CD14+ cells, while monocytes did not induce T cell proliferation at both conditions. The 
reduced capacity to induce T cell proliferation of R848 stimulated BDCA1+CD14+ cells despite 
increased levels of co-stimulatory molecules (Figure 18) could be addressed to a reduced 
viability after R848 stimulation (Figure 20). By contrast, the same stimulation increased 
survival of BDCA1+CD14- DCs and probably supported the co-stimulatory molecule dependent 
T cell proliferative capacity (Figure 19). Thus, BDCA1+CD14+ cells were similar to DCs rather 
than to monocytes in function by regulation of stimulatory molecules and induction of T cell 
proliferation. Their inflammatory properties were reminiscent of inflammatory DCs found in 
inflamed tissues174, however, in contrast to blood BDCA1+CD14+ cells, inflammatory DCs were 
only found during inflammation170,171,193. Thus, due to their similarity to inflammatory DCs174 
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and pro-inflammatory properties but constant presence in blood, BDCA1+CD14+ cells are 
therefore further on referred to as pro-inflammatory DCs (pro-iDCs). 
Figure 18 BDCA1+CD14+ cells are similar to BDCA1+CD14- DCs in terms of T cell stimulatory molecule expression 
Magnetically enriched BDCA1+CD14- DCs, BDCA1+CD14+ cells and CD14+CD16-BDCA1- monocytes from CD19 
depleted PBMC were cultured in the presence of depicted TLR agonists and cytosolic delivered poly A:T dsDNA 
using Lipofectamin 2000 (pA:T + LF2000). After 24h, expression levels of CD40, CD80, CD83, CD86, HLA-ABC and 
HLA-DR were assessed by flow cytometry. Shown are average median fluorescence intensities of 3 experiments. 
Error bars represent SEM.
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5.6 Cytokines secreted by ex vivo pro-iDCs drive APC maturation in trans 
Pro-inflammatory cytokines have extensive effects on the immune system including induction 
of maturation of professional APCs151,259,260. An early study by Jonuleit et al.151  demonstrated 
that cytokines including IL-1β, IL-6 and TNFα are able to induce maturation and augment the 
T cell stimulatory capacity of DCs differentiated from monocytes. Since ex vivo pro-iDCs 
produce vast amounts of pro-inflammatory cytokines that partly resembled the cocktail used 
by Jonuleit et al., the impact of pro-iDC derived culture supernatants on APC maturation was 
assessed.  
Figure 21 Pro-iDC derived culture supernatants induce maturation of conventional DCs 
Magnetically isolated BDCA1+CD14- DCs, BDCA3+CD14- DCs, plasmacytoid DCs (pDCs) and CD14+CD16-BDCA1- 
monocytes of CD19 depleted PBMC were cultured in the presence or absence of culture supernatants derived 
from BDCA1+CD14- DCs, CD14+CD16-BDCA1- monocytes and pro-iDCs, which were cultured for 24h without 
stimulation. Afterwards, cells were analyzed for expression levels of CD40, CD80, CD83 and CD86 by flow 
cytometry. Average median fluorescence intensities (MFI) of 5 experiments are shown. Error bars represent SEM. 
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In an allogeneic T cell co-culture, pro-iDC derived supernatants treated BDCA1+CD14- DCs and 
BDCA3+CD14- DCs gained a strong capacity to induce T cell proliferation, whereas other 
supernatants or untreated APCs failed to do so. In line with their inability to upregulate co-
stimulatory molecules (Figure 21), CD14+CD16- monocytes did not promote T cell growth. 
Since BDCA3+CD14- DCs could not be obtained in similar high numbers as BDCA1+CD14- DCs 
from peripheral blood, they were co-cultured at an average number of 6.3x103 cells and only 
treated with pro-iDC derived supernatants or left unstimulated. In accordance with the higher 
expression of co-stimulatory molecules before and after treatment with pro-iDC derived 
supernatants, BDCA3+CD14- DCs induced a stronger T cell proliferation when compared to 
BDCA1+CD14- DCs.  
5.7 Inflammatory cytokines secreted by ex vivo pro-iDCs support T cell proliferation 
As inflammatory cytokines including IL-1β, IL-6 and TNFα promote T cell growth263-267 and as 
these were found in large amounts in culture supernatants from ex vivo pro-iDCs (Figure 7), 
their influence on T cell proliferation was analyzed. Naïve T cells require TCR and co-
stimulatory molecule stimulation for proliferation. To assess the impact of cytokines, an 
experimental setting was necessary in which the requirement for TCR and co-stimulation was 
given but at an intensity that was below the threshold for productive T cell expansion. To 
achieve this, T cells were cultured in the presence of beads coupled to low amounts of 
antibodies recognizing CD3 and CD28, which are part of the TCR and co-stimulatory 
molecules268. At this setting, T cells cultured in the presence of beads alone basically failed to 
proliferate (Figure 23, medium). In line with the high levels of inflammatory cytokines found 
in supernatants from freshly isolated and 24h cultured pro-iDCs (Figure 7 A), naïve CD4+ T cells 
cultured in the presence of pro-iDC derived supernatants induced a considerable T cell 
proliferation when compared to BDCA1+CD14- DC derived supernatants (Figure 23 A). As TLR 
stimulated BDCA1+CD14- DCs secreted similar amounts of inflammatory cytokines when 
compared to ex vivo pro-iDCs (Figure 7), supernatants from R848 treated BDCA1+CD14- DCs 
and untreated pro-iDCs induced a strong T cell proliferation at comparable levels. To 
determine the impact of single cytokines contained in pro-iDC derived supernatants on T cell 
proliferation, IL-1β, IL-6 and TNFα were blocked using neutralizing antibodies in a subsequent 
experiment (Figure 23 B). Neutralization of IL-6 and followed by TNFα decreased the extent of 
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T cell proliferation the most, whereas IL-1β neutralization had only a minor impact. 
Remarkably, IL-1β, IL-6 and TNFα present in pro-iDC derived supernatants exclusively drove T 
cell proliferation as combined neutralization of these cytokines abrogated proliferation to the 
basal level. The proliferative capacity was specific to the cytokines, as respective isotype 
antibody controls did not influence the intensity of T cell proliferation. The individual impacts 
of IL-1β, IL-6 and TNFα on T cell proliferation were confirmed in an experimental setting using 
recombinant cytokines. These induced T cell proliferation at the same magnitude as 
neutralization of these cytokines from pro-iDC derived supernatants decreased T cell 
proliferation (Figure 23 C). Combined treatment with IL-1β, IL-6 and TNFα induced the 
strongest T cell division, whereas single treatment with TNFα weakly increased proliferation 
and IL-1β alone had no effect. 
Until now, the superior capability of ex vivo pro-iDCs to induce the strong T cell proliferation 
as seen in the allogeneic co-culture (Figure 19, medium) could not be explained, as the 
expression of co-stimulatory molecules did not highly differ from freshly isolated (Figure 4) or 
24h cultured BDCA1+CD14- DCs (Figure 18). Instead, the influence of the cytokines secreted by 
pro-iDCs may explain their major T cell proliferative capacity. 
T cells were activated at the same time by pro-iDC derived cytokines measured by CD25 
expression (Figure 23 D). TNFα activated T cells the most, as its neutralization mediated the 
strongest decline in CD25+ T cells. Neutralization of IL-6 slightly increased the percentage of 
CD25 expressing T cells. Taken together, pro-iDCs may support immune responses in trans by 
the secretion of pro-inflammatory cytokines that augments APC activation and T cell 
proliferation.  
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5.8 Pro-iDCs can be recruited from monocytes 
(Collection of blood samples from RA patients was done by PD Dr. Eugen Feist and 
acquisition was performed by Stefanie Gamradt, both at the Charité, Berlin) 
Ly6Chi monocytes, which are murine orthologs of CD14+CD16- monocytes207, differentiate 
towards inflammatory DCs under inflammatory conditions174. In humans, the inflammatory 
DC character of pro-iDCs (Figures 7 and 17) correlates with the mouse model in terms of T cell 
polarization and cytokine secretion170. In addition, the high phenotypic similarity between 
pro-iDCs and CD14+CD16- monocytes (Figure 4) suggests a monocytic origin of pro-iDCs. To 
test this hypothesis, CD14+CD16- monocytes were cultured for 24h and 48h under 
inflammatory conditions using stimuli including pro-iDC derived supernatants, a cocktail of 
recombinant cytokines comprised of IL-1β, IL-6, PGE2, TNFα, GM-CSF and IL-4 or controls 
including BDCA1+CD14- DC and CD14+CD16- monocyte derived supernatants (Figure 24 A). As 
pro-iDCs can be identified by BDCA1 expression from monocytes, so cultured CD14+CD16- 
monocytes were subsequently analyzed for BDCA1 expression. Pro-iDC derived supernatants 
and the cocktail of recombinant cytokines induced detectable levels of BDCA1 already after 
24h. Almost 50% of the cells expressed significant amounts of BDCA1 after 48h of treatment 
with the cocktail of recombinant cytokines (Figure 24 B). By contrast, LPS or other cell derived 
supernatants had no effect. Since pro-iDC derived culture supernatants include high levels 
inflammatory cytokines and control supernatants from cultured BDCA1+CD14- DC and 
CD14+CD16- monocyte lack these (Figure 7 A), BDCA1 expression on CD14+CD16- monocytes 
was suggested to be triggered by pro-inflammatory cytokines. To identify the key cytokines 
that drive BDCA1 induction on CD14+CD16- monocytes, cytokines were considered that were 
present in both, the cocktail and in pro-iDC derived supernatants (Figure 24 C) including IL-1β, 
IL-6 and TNFα. In line with the requirement of IL-1R mediated signaling for murine 
inflammatory DC differentiation from monocytes269,270, IL-1β induced BDCA1 expression on 
CD14+CD16- monocytes, while IL-6 and TNFα had no effect. However, IL-1β and IL-6 synergized 
in inducing up-regulation of BDCA1 in the early phase of differentiation, however, this effect 
vanished after 48h. To show whether CD14+CD16- monocytes had differentiated into DCs and 
not only gained BDCA1 expression alone, DC differentiation can be functionally analyzed by 
the capacity to induce T cell proliferation271. In contrast to R848 treated BDCA1- or 
unstimulated CD14+CD16- monocyte controls, inflammatory cytokine activated CD14+CD16-
BDCA1+ cells significantly increased the number of allogeneic naïve CD4+ T cells (Figure 24 D). 
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Thus, under inflammatory conditions CD14+CD16- monocytes not only acquired a phenotype 
resembling pro-iDCs by BDCA1 expression but had also developed into DCs, capable of 
inducing proliferation of T cells. So far, no studies could show the recruitment and DC 
differentiation in humans in vivo. As an approach to analyze whether pro-iDC differentiation 
under inflammatory conditions occurs in vivo, numbers of BDCA1+CD14- DCs and pro-iDCs 
from peripheral blood were assessed in patients suffering from rheumatoid arthritis (RA) and 
compared to equivalent numbers of healthy donors (Figure 24 E). As DC migration from blood 
to tissues was shown to be associated with RA and results in a lower abundance in blood272,273, 
BDCA1+CD14- DCs from RA patients showed reduced numbers when compared to healthy 
donors. The same reason might hamper the acquisition of pro-iDCs and therefore assessed 
numbers can be considered lower than numbers of actually differentiated cells. In addition, 
the cell count might be influenced by chemotaxis mediated by the chemokine receptor CCR5 
that is involved in leukocyte migration to RA synoviums274. Since pro-iDCs express over 20 fold 
higher levels of CCR5 when compared to BDCA1+CD14- DCs (Figure 4), numbers of pro-iDCs 
were expected to be decreased in blood obtained from RA patients. However, numbers of 
pro-iDCs were slightly increased in RA patients compared to healthy donors. This indicates an 
ongoing recruitment and differentiation from monocytes towards pro-iDCs already in 
peripheral blood in vivo.  
Figure 24 (next page) BDCA1+CD14+ cells with a strong DC function can be induced from CD14+CD16-BDCA1- 
monocytes   
CD14+CD16-BDCA1- monocytes were treated with culture supernatants derived from BDCA1+CD14- DCs, pro-iDCs, 
BDCA1-CD14+CD16- monocytes, LPS and a cocktail of inflammatory cytokines containing IL-1β, IL-6, TNFα, GM-
CSF, IL-4 and PGE2. After 24h and 48h, frequencies of BDCA1 expressing cells were assessed by flow cytometry 
(A). One representative example from inflammatory cytokine treated cells is shown as a histogram plot (B). 
Monocytes were treated with IL-1β, IL-6 and TNFα or combinations thereof and BDCA1 induction was assessed 
after 24h and 48h (C). To assess DC function, CD14+CD16-BDCA1- monocytes were cultured in the presence of 
R848, the cocktail of inflammatory cytokines mentioned above or medium alone for 24h, washed intensively and 
co-cultured with allogeneic naïve CD4+ T cells (D). After 6 days, numbers of T cells according to CD3 expression 
were assessed using flow cytometry (n=5). To evaluate whether pro-iDCs were recruited during inflammation, 
numbers of BDCA1+CD14- DCs and BDCA1+CD14+ pro-iDCs were determined in peripheral blood from 8 patients 
suffering from rheumatoid arthritis (RA) and compared to healthy donors. For the calculation of absolute cell 
numbers refer to material and methods (E). Error bars represent SEM. 
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5.9 Transcriptome analysis indicates dendritic cell character of pro-iDCs 
(Microarray raw data processing was performed by Michail Knauel and Figures 26-28 were 
generated by Dr. Jutta Kollet at Miltenyi Biotec) 
By phenotypic analysis, pro-iDCs appeared to be highly related to CD14+CD16- monocytes but 
endowed with key DC properties (Figures 4, 7, 18). In addition, CD14+CD16- monocytes gave 
rise to pro-iDC resembling BDCA1+CD14+ cells with DC function under inflammatory conditions 
in vitro (Figure 24). In order to elucidate the affiliation of pro-iDCs, the transcriptome of pro-
iDCs was compared to that of CD14+CD16-BDCA1- monocytes, BDCA1+CD14- DC and 
BDCA3+CD14- DC and in vitro generated immature and mature monocyte derived DCs (imoDCs 
and mmoDCs). To analyze the reliability of the microarray analysis, mRNA expression levels of 
relevant markers were compared to corresponding protein levels: correlation was proven for 
BDCA1, CD14, HLA-DR, CD40 and CD36 levels (Figures 4 and 25). 
Figure 25 Relative gene expression levels of selected genes correlate with protein expression levels on monocytes 
and different DC subsets 
Data was generated from ex vivo samples of flow sorted pro-iDCs, CD14+CD16-BDCA1- monocytes, BDCA1+CD14- 
DCs and BDCA3+CD14- DCs and in vitro generated immature and mature monocyte derived DCs (imoDC, mmoDC). 
Shown are relative mRNA expression levels from normalized whole genome microarray experiments of the 
selected genes BDCA1, CD14, HLA-DRA, HLA-DRB, CD40 and CD36. Error bars represent SEM. 
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development from monocyte towards DC may be reflected by the 680 differentially expressed 
genes between CD14+CD16-BDCA1- monocytes and pro-iDCs. To prove this hypothesis, 
expression of these genes was correlated each between pro-iDCs and CD14+CD16- monocytes, 
BDCA1+CD14- DC, BDCA3+CD14- DC, imoDCs and mmoDCs (Figure 27).  
Figure 27 Trend analysis of differentially regulated genes between pro-iDCs and CD14+CD16-BDCA1- monocytes 
revealed the highest correlation between pro-iDCs and BDCA1+CD14- DCs 
Log2 median signal intensities of pro-iDCs of >2 fold differentially regulated genes between pro-iDCs and 
CD14+CD16-BDCA1- monocytes were correlated in pair-wise scatter plots with CD14+CD16-BDCA1- monocytes, 
BDCA1+CD14- DCs, BDCA3+CD14- DCs, imoDCs and mmoDCs. Red dots indicate transcripts stronger expressed in 
pro-iDCs and genes indicated by green dots are higher expressed in CD14+CD16-BDCA1- monocytes. Numbers in 
the plots indicate p-values and correlation coefficients. 
Transcripts that were higher expressed in pro-iDCs over CD14+CD16- monocytes (red circles) 
were widely higher expressed in all DC subsets tested, whereas transcripts higher regulated in 
CD14+CD16- monocytes (green circles) were generally lower expressed in the DC subsets. 
Among subsets compared to pro-iDCs, the gene expression profile correlated the most with 
BDCA1+CD14- DCs (correlation coefficient (cor)=0.837), which was clearly above CD14+CD16- 
monocytes (cor=0.764) and followed by imoDC (cor=0.706), BDCA3+CD14- DCs (cor=0.701) and 
mmoDCs (cor=0.658). Thus, the regulation of these genes in pro-iDCs pointed to a DC 
affiliation or an ongoing development towards DC.  
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To further analyze the DC affiliation of pro-iDCs on a single gene level, differentially expressed 
genes were subjected to annotation enrichment analysis and resulting gene clusters were 
analyzed for associations with dendritic cells and monocytes (Figure 28).  
Figure 28 Term enrichment analysis revealed a DC expression profile in pro-iDCs 
Genes >2 fold differentially regulated between pro-iDCs and CD14+CD16-BDCA1- monocytes with significant term 
enrichment in DC or monocyte specific categories were hierarchically clustered (Euclidean distance, complete 
linkage). Cell samples included pro-iDCs (green), CD14+CD16-BDCA1- monocytes (blue), BDCA1+CD14- DCs 
(orange) and BDCA3+CD14- DCs (black) and in vitro generated immature monocyte derived DCs (imoDC, red) and 
mature moDC (mmoDC, yellow). The range of the log2 sample intensities was centered to monocytes and set to 
-10 (green) to 10 (red). The adjacent color bar indicates genes associated with dendritic cells (red) and monocytes 
(green). 
Hierarchical clustering of genes associated with these associations revealed a higher similarity 
to BDCA1+CD14- DCs than to CD14+CD16- monocytes. DC specific genes were selectively 
upregulated in pro-iDCs and the other tested DC subsets, whereas monocyte specific genes 
were downregulated in pro-iDCs and other DC subsets. Among the analyzed cluster of genes, 
mRNA levels of transcription factors involved in DC differentiation including IRF4102-105 and 
BATF3106-108 and the transcription factor ZBTB46, recently described as specific for 
conventional DC lineage110,275, were >3.5 fold upregulated in pro-iDCs over CD14+CD16- 
monocytes. Furthermore, DC specific genes including LAMP3276, TNFRSF11A277, PLXNA1278 and 
UBD279 were regulated in the same way. Especially genes involved in T cell stimulation (CD276) 
imoDC mmoDC pro-iDC 
CD14+CD16- 
Monocyte 
BDCA1+CD14- 
DC 
BDCA3+CD14- 
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and antigen presentation including CD74, HLA-DQ, HLA-DRA, HLA-DRB, CD1C (BDCA1) and 
CD1E and were >2 fold upregulated in pro-iDCs over CD14+CD16- monocytes.  
The inflammatory character of pro-iDCs was underlined by >5 fold stronger expression of the 
TH1 and NK cell attracting and TH2 inhibitory chemokine CXCL9280-282. In contrast to the protein 
level (Figure 4), the transcript of the inflammatory DC marker MRC1L1 (CD206, mannose 
receptor)169,283 was 21 fold higher regulated in pro-iDCs over CD14+CD16- monocytes, while 
the higher protein expression of monocyte/macrophage marker CD163 (Figure 4) could not 
be confirmed on gene level. As protein level regulation commonly lags behind gene expression 
levels284, a strongly increased mRNA level of MRC1L1 supports the hypothesis of an ongoing 
development towards DC. Genes that were described to be specifically enriched in both, 
macrophage and DC lineages including TIFAB285, CLEC10A286 and GAS6287,288, were >2 fold 
stronger expressed in pro-iDCs over monocytes. In addition, genes differentially regulated 
between pro-iDCs and monocytes did not indicate an affiliation or an ongoing development 
towards macrophages as these lacked macrophage specific transcription factors including 
STAT1, STAT3, STAT6289 and VENTX290 and genes involved in macrophage differentiation EGR2, 
EMR1, MAFB291 and macrophage markers ITGB2, LAMP2 and CD68292. Moreover, EGR1 that is 
involved in macrophage differentiation293 was >2 fold lower expressed in pro-iDCs compared 
to monocytes. RUNX3 expression positively correlates with long-term expression of CD4/CD14 
in monocytes and macrophages222. Hence, the >3.5 fold lower expression of RUNX3 in pro-
iDCs compared to CD14+CD16- monocytes further indicates a differentiation towards DC.  This 
in line with a decreased CXCR4 protein expression on pro-iDCs versus monocytes (Figure 4), 
as CXCR4 dependent signaling mediated by CXCL12 leads to increased RUNX3 levels and 
thereby prevents monocyte differentiation towards DC225. The highest regulated genes in pro-
iDCs are C1QA, C1QB and C1QC with a 47 to 140 fold higher expression over CD14+CD16- 
monocytes. The translated genes form the heterotrimeric protein C1q, which belongs to the 
complement factors294. As C1q expression is restricted to DCs and lacks in monocytes295-298, 
the very high expression of its subunits C1QA, C1QB and C1QC genes further pointed to a 
differentiation of pro-iDCs towards DCs. In contrast, monocyte specific genes including 
VNN2299 and CSF3R145,300 were 18 and 2 fold higher regulated in CD14+CD16- monocytes over 
pro-iDCs, respectively. Based on genes that were >2 fold differentially expressed between pro-
iDCs and monocytes, an annotation enrichment analysis using the publically available 
database GeneOntology301 was performed. Terms that were most enriched in an annotation 
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analysis based on genes >2 fold higher expressed in pro-iDCs over CD14+CD16- monocytes 
indicated key DC functions302-304 in pro-iDCs, which included antigen processing/presentation 
and T cell activation (Figure 29). This set included DC specific genes CD1B, CD1C, CD1E, 
HLA-DR, HLA-DQ and UBD. Thus, despite the high similarity to monocytes on protein (Figure 
4) and whole genome level, upregulation of DC-specific transcription factors, DC-specific cell
surface molecules and downregulation of transcripts involved in macrophage differentiation 
and monocyte maintenance and functional enrichment of genes involved in antigen 
presentation and T-cell stimulation indicate an ongoing developmental program towards DC.  
Figure 29 GeneOntology term analysis reveals an enrichment in genes involved in DC function in pro-iDCs 
Genes selected from transcripts >2 fold differently expressed between pro-iDCs and CD14+CD16-BDCA1- 
monocytes were analyzed for term enrichment. Significant enrichments based on the publically available 
database GeneOntology (GO)301 in “GO Biological Process” are shown for terms with a minimal gene count >10, 
a minimal enrichment >7 and p<10-6. 
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5.10 Cells phenotypically resembling pro-iDCs are present in inflamed tissues 
(Data was generated by Christian Ostalecki at the University of Erlangen)  
To date, there is no solid data on the characterization of human monocyte derived DCs in vivo. 
However, Ly6Chi monocytes, which are murine counterparts of human CD14+CD16- 
monocytes207 migrate to inflamed tissue and differentiate in response to inflammatory factors 
towards inflammatory DCs172,173,186. As to date human inflammatory DCs were only found at 
the site of inflammation168-170 and this work suggests pro-iDCs to be precursors of 
inflammatory DCs. Thus, samples of human inflamed skin were analyzed for the presence of 
cells with phenotypic characteristics of blood pro-iDCs. 
The presence and phenotype of cells present in the skin were analyzed in situ on the basis of 
BDCA1 and CD14 co-expression by making use of an imaging technique (multiple epitope 
ligand cartography, MELC) that allows the analysis of multiple parameters on the same 
specimen (Figure 30). Skin samples from individuals suffering from psoriasis, 
dermatomyositosis and inflamed halo nevus or from healthy donors were analyzed for 
leukocyte infiltration. All specimens were infiltrated by CD45+ leukocytes (Figure 30 A-D, 
CD45+ red). Of note is, that in inflamed skin, cells were abundantly distributed, whereas 
leukocytes localized strictly around blood vessels in healthy skin. As B cells express also BDCA1 
and in addition to CD20, B cells cannot be distinguished from BDCA1+ DCs and thus CD20+ cells 
were excluded from the following analysis. Similar to mouse inflammatory DCs172,173,186, 
human BDCA1+CD14+ cells (arrows) were present in inflamed but not in healthy skin, indicating 
that these cells are not tissue resident but might be rather recruited to sites of inflammation 
(Figure 30 E-H). In contrast, in healthy skin only single positive BDCA1+CD14- DC (red) and 
BDCA1-CD14+ cells (green) were detected. For deeper characterization besides CD45, BDCA1 
and CD14, skin sections were analyzed for the expression of multiple cell surface markers and 
cytokines, which have been previously shown to be associated with the pro-iDC phenotype 
(Figure 30 I). As shown for one representative BDCA1+CD14+ cell from psoriatic skin, cells were 
positive for human inflammatory DC markers BDCA1, CD14, CD1a, CD11b, CD206, FcεR1α and 
HLA-DR168-170,305 and also for CD40, CD45, CD68, CX3CR1. Lower expression was observed for 
CD45RA, CD63, CD163, CD276 and IFNα. BDCA1+CD14+ cells were distinct from T cells, CD16+ 
monocytes, B cells and BDCA3+ DCs by the lack of CD3, CD8, CD16, CD20 and CLEC9a 
expression, respectively. BDCA1+CD14+ cells show not only a high similarity with human 
inflammatory DCs170, they resemble pro-iDCs isolated from peripheral blood to a high degree. 
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Thus, the high convergence between pro-iDCs and BDCA1+CD14+ cells found here with high 
similarities to inflammatory DCs170 strongly suggests that pro-iDCs may represent the 
immediate precursor of inflammatory DCs in tissues. 
Figure 30 (next page) BDCA1+CD14+ cells present in inflamed tissues resemble inflammatory DCs 
Skin samples from healthy donors or patients suffering from psoriasis, dermatomyositis and inflamed halo nevus 
were analyzed using multiple epitope ligand cartography (MELC), a technology allowing the assessment of 
multiple parameters on a single sample. The samples show subepidermal skin layers indicated by cytokeratin 14 
(grey), blood vessels by collagen IV (blue). Leukocytes (CD45+ cells) are colored red. Scale bar: 100µm (A-D). 
BDCA1 (red), CD14 (green) and collagen IV (blue) are shown on the same samples. Scale bar: 10µm (E-H). 
BDCA1+CD14+ cells are highlighted by arrows. A representative BDCA1+CD14+ cell from psoriatic skin is depicted 
and indicated markers are shown. Scale bar: 50µm (I). 
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6 Discussion 
This work describes a novel BDCA1+CD14+ myeloid DC subset with high phenotypic similarity 
to monocytes, but endowed with a decisive dendritic cell gene signature and function. The 
cells spontaneously secreted vast amounts of inflammatory cytokines, mediated TH17 
polarization and augmented T cell proliferation. BDCA1+CD14+ DCs constitute a yet 
uncharacterized cell type with inflammatory properties and were therefore termed 
pro-inflammatory DCs (pro-iDCs).  
Although visualized by flow cytometry analysis by BDCA1/CD14 expression for the first time 
over 10 years ago222, a detailed characterization of pro-iDCs, especially the cellular affiliation 
and function remained elusive. The lack of data could be addressed to methodical obstacles 
that complicated a detailed analysis, including low cell numbers, low expression of the 
distinguishing dendritic cell marker BDCA1 and thus difficult discrimination from monocytes. 
Data obtained in this study showed a very high similarity of pro-iDCs with monocytes, 
however, pro-iDCs differed from monocytes in functions and expression of markers on gene 
and protein level in a manner that pointed to a DC affiliation. The high overall similarity with 
monocytes suggested that pro-iDCs have a monocytic origin. The lack of CD16 and SLAN 
expression on pro-iDCs excluded an affiliation with CD14dimCD16+ monocytes or the SLAN DC 
subset thereof207. Instead, pro-iDCs were most similar to the CD14+CD16- monocyte subset, 
as both cell types expressed comparable levels of CD14 and were only distinguishable from 
each other by few markers as obtained in flow cytometry. As monocytes have the capability 
to differentiate into DCs and macrophages199, we tried to classify pro-iDCs with known DC and 
macrophage markers to get a first impression on their ontogeny. Pro-iDCs expressed elevated 
levels of activated DC markers including BDCA1, CD40 and CD54 when compared to 
monocytes, and high levels of HLA-DR resembling BDCA1+CD14- DCs. In terms of typical 
macrophage markers234,292, pro-iDCs lacked CD68 but expressed CD163 at high levels. To gain 
further insight into the classification besides phenotypic analysis on protein level, a 
transcriptome expression analysis was performed with pro-iDCs. 
As most of the genes of pro-iDCs and CD14+CD16- monocytes were regulated in the same way, 
genes differentially expressed between these subsets were used to characterize pro-iDCs. A 
macrophage affiliation was unlikely as genes higher regulated in pro-iDCs over monocytes did 
neither include the macrophage specific transcripts VENTX290, STAT1, STAT3, STAT6289 nor 
known genes involved in macrophage differentiation EGR1293, EGR2, EMR1, MAFB291. Instead 
Discussion 
72 
the few genes higher regulated in pro-iDCs over monocytes included the DC transcription 
factors ZBTB46110,275, IRF4102-105 and BATF3106-108 and DC specific genes including LAMP3276, 
TNFRSF11A277, PLXNA1278 and UBD279. Trend analysis of differentially expressed genes 
between pro-iDCs and CD14+CD16- monocytes applied to various DC subsets and monocytes 
revealed the highest correlation between pro-iDCs and BDCA1+CD14- DCs.  Furthermore, all 
genes that were higher expressed in pro-iDCs compared to CD14+CD16- monocytes were even 
higher expressed in the cDC and moDC subsets, emphasizing their association with DCs. The 
same was true for genes lower expressed in pro-iDCs than in CD14+CD16- monocytes. Clusters 
of genes that are known to be part of cellular processes can be associated to terms using the 
publically available database GeneOntology301. Term enrichment analysis based on genes 
higher expressed in pro-iDCs over monocytes revealed terms including antigen 
processing/presentation and T cell activation, which are key DC functions302-304. Functional 
evidence on the capacity of pro-iDCs to induce T cell activation and proliferation supported 
the association of pro-iDCs with DCs, although T cell proliferation was presumably in part 
dependent on the lowering of the activation threshold by the secretion of inflammatory 
cytokines. In terms of responsiveness to PRR stimulation, pro-iDCs expressed several co-
stimulatory molecules such as CD40 and CD80 in a way resembling BDCA1+CD14- DCs and not 
CD14+CD16- monocytes after TLR triggering. In conclusion, phenotype, transcriptome and 
function suggest that pro-iDCs are an intermediate subset between monocytes and DCs, and 
it is interesting to speculate that they differentiate from human monocytes in vivo.  
In mice, evidence of monocyte differentiation into DCs in vivo has been established174. In 
contrast to naturally occurring DCs, which are derived from a common DC precursor199, 
inflammatory DCs are derived from Ly6Chi monocytes under inflammatory conditions172,269,270. 
In humans, DCs can be generated from monocytes in the presence of inflammatory cytokines 
in vitro149,151. Even though moDC differentiation in vivo is anticipated170,171 real evidence and 
underlying mechanisms are lacking. Although a consistent human precursor has not been 
identified yet, transcriptome and phenotypical analysis led to the speculation that blood 
monocytes might give rise to inflammatory DCs170,171. It is thus interesting to discuss whether 
human monocytes give rise to pro-iDCs in vivo and which mechanisms may be involved. Based 
on previous findings151, we chose to induce monocyte differentiation using a cocktail of IL-4, 
GM-CSF, IL-6, TNFα, PGE2 and IL-1β. Indeed, we found that these cytokines induced the 
acquisition of DC functions including induction of T cell proliferation in differentiated 
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monocytes. In a number of studies, PGE2 was shown to have enhancing and modulating effects 
on DCs in terms of T cell proliferation and cytokine induction rather than a role in inducing DC 
differentiation151,306-308. Also reported by several groups, IL-1β induced the secretion of IL-6 
and TNFα from blood mononuclear cells250,251,309. Hence, we sought to determine whether IL-
1β alone is sufficient to induce monocyte differentiation. Strikingly, we found that IL-1β 
treated CD14+CD16- monocytes started to express the DC marker BDCA1 at comparable levels 
as pro-iDCs. This is an important finding since CD14+CD16- monocytes are orthologs of murine 
Ly6Chi monocytes that have been reported to differentiate into inflammatory DCs in the 
presence of inflammatory stimuli. We further found that IL-1β alone triggered the secretion 
of GM-CSF, TNFα and IL-6 from pro-iDCs. Thus, we believe that the addition of these cytokines 
into the differentiation cocktail is not necessary as IL-1β stimulation may lead in part to 
autocrine supply of moDC differentiation factors in pro-iDCs. In line with this, observations 
from studies in mice point to a pivotal role for IL-1β in DC differentiation from monocytes. For 
mouse Ly6Chi monocytes, a MyD88 dependent signal, as determined by MyD88-KO animals, 
was required for the differentiation towards inflammatory DCs and Tip-DCs under 
inflammatory conditions180,188,269,270,310. In a Brucella melitensis infection model, a MyD88 
dependent signal was required but receptors mediating the signaling were interchangeable, 
as the absence of a single TLR could be substituted by another TLR, and Tip-DCs were still 
induced albeit at reduced frequencies188. Other studies described the differentiation of 
monocytes towards inflammatory DCs in a NLRP3 inflammasome and MyD88 dependent way 
during sterile inflammation induced by alum269,270. As NLRP3 inflammasome induction leads 
to IL-1β and IL-18 secretion, autocrine and MyD88 dependent IL-1R and IL-18R signaling could 
be considered to be crucial for inflammatory DC differentiation. Of note, IL-1β signaling 
induces IRF4 expression311 in humans that is associated with DC differentiation105. Although 
this observation was made in CD4+ T cells, a similar regulation in monocytes is to be expected 
as IL-1R signaling in both monocytes and T cells employ MyD88 dependent NF-κB and MAPK 
pathways312-314. In contrast to mice, where MyD88 signaling mediated by interchangeable 
TLRs induced monocyte differentiation into inflammatory DCs172, human monocytes are less 
promiscuous. Human monocytes do not differentiate towards DCs in response to TLR7/8 
dependent R848 stimulation315 and according to established protocols, LPS stimulation is not 
sufficient to drive DC differentiation from monocytes149,151. In line with the data presented in 
this work, MyD88 dependent TLR8 and TLR4 signaling mediated by R848 and LPS were not 
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sufficient to induce moDC differentiation as shown by the lack of BDCA1 expression and DC 
function. Instead, IL-1β stimulation of CD14+CD16- monocytes induced BDCA1+CD14+ cells 
reminiscent of pro-iDCs. Thus, in humans, moDC differentiation may occur in vivo already 
under steady state conditions as indicated by blood resident pro-iDCs obtained from healthy 
donors. These may be induced by IL-1R signaling, as IL-1β stimulation led to BDCA1+ pro-
inflammatory DC differentiation from CD14+CD16- monocytes. This hypothesis is emphasized 
as this work revealed increased numbers of pro-iDCs in blood from patients suffering from RA 
when compared to healthy donors. It thus indicates that pro-iDCs are mobilized from 
progenitor cells during inflammation in a way resembling the fate of murine Ly6Chi monocytes. 
Interestingly, inflammatory DCs recently been described by Segura et al.170 were found in 
synovial fluids from RA patients. Strikingly, they showed a high similarity to pro-iDCs found in 
this study, both in terms of phenotype and function but also differed in some aspects. Both 
subsets were similar in marker expression including BDCA1, CD14, HLA-DR, CD11b, CD172a, 
and absence of CD16 and CD209. Functionally, both cell types secreted large amounts of 
inflammatory cytokines, induced TH17 responses and drove T cell proliferation. However, in 
contrast to inflammatory DCs found in RA, pro-iDCs lacked FcεR1α and CD206 expression. As 
IL-4 was described to induce FcεR1α protein expression316, the expression of FcεR1α on 
inflammatory DCs found at the site of inflammation and the lack on blood pro-iDCs may be 
due to factors present only in inflamed tissues. Despite the absence of the CD206 protein, pro-
iDCs expressed its transcript at very high levels, which were 21-fold higher than in CD14+CD16- 
monocytes. Post-transcriptional control of MRC1L1/CD206 translation could inhibit protein 
expression, which may be reversed by factors only present in inflamed environments. When 
compared to blood cells, no other population showed a higher convergence with 
inflammatory DCs than pro-iDCs. As the authors speculated a blood monocyte origin of 
inflammatory DCs170 and pro-iDCs are likely to originate from monocytes, pro-iDCs may be 
regarded as an intermediate development stage between blood monocytes and DCs and an 
intermediate progenitor to inflammatory DCs found in inflamed tissues. Thus, the existence 
of pro-iDCs in blood may support their hypothesis that inflammatory DCs found in inflamed 
tissues originate from blood monocytes170. Other types of human inflammatory DCs have 
been found in different diseases, and despite divergences in phenotype and function, they 
were all termed inflammatory DCs. Wollenberg et al.169 described inflammatory dendritic 
epidermal cells (IDECs) present in several autoimmune diseases including atopic dermatitis 
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and psoriasis. Among the few markers they analyzed, IDECs did not share the expression of 
markers with pro-iDCs. However, it is interesting to speculate that both cell types can be 
related considering that pro-iDCs are precursors of BDCA1+CD14+ cells, which we found in 
psoriatic skin, since IDECs and BDCA1+CD14+ cells shared the expression of CD1a, CD206 and 
FcεR1α. Zaba et al.171,205 further described an inflammatory Tip-DC subset present in psoriatic 
skin. This subset was also distinct from blood pro-iDCs and were characterized as TNFα+, IL-
23+, iNOS+, CD11c+ and BDCA1-. Contrary to pro-iDCs, Tip-DCs did not express BDCA1, and key 
monocyte/macrophage and DC specific mRNA levels including CD163, CD68, CD14, EGR1, 
VNN2 and CD1E were also differently regulated. In contrast to the relationship of pro-iDCs 
with CD14+CD16- monocytes found in this work, BDCA1- Tip-DCs were discussed to be derived 
from inflammatory CD14+CD16+ monocytes based on transcriptome profiling207, and might 
represent a distinct subset of inflammatory DCs. In contrast, another type of inflammatory 
DCs present in Crohns disease317, an autoimmune disease affecting the gastrointestinal tract, 
is similar to blood pro-iDCs and inflammatory DCs from rheumatoid arthritis (RA)170. They 
were described as CD14+, HLA-DRhi, CD172a+, IL-1β+, TNFα+ but lacked BDCA1 expression. 
Interestingly, all types of the before mentioned inflammatory DCs shared the presence in 
inflammatory diseases, were absent in healthy tissues and, where analyzed, had a strong 
capacity to induce TH1/TH17 cells. Although all authors speculated a monocytic 
origin170,171,317,169, inflammatory DCs isolated from different pathological environments show 
phenotypic heterogeneity. This is similar to in vitro generated moDCs, as monocytes give rise 
to DCs with various phenotypes and functions dependent on the factors used for their 
differentiation148. In this respect, monocytes may differentiate towards inflammatory DCs 
with varying phenotypes and functions. However, it is still open whether these cells originate 
from different or common progenitors.  
The synthesis and release of cytokines is a crucial function of DCs to induce defined signaling 
pathways in target cells. Similar to inflammatory DCs170,171,317 found in inflamed tissues, 
pro-iDCs secreted vast amounts of inflammatory cytokines. Whereas the release of cytokines 
from unstimulated inflammatory DCs isolated from inflamed tissues could be addressed to 
environmental factors, the spontaneous release of cytokines from blood pro-iDCs was 
unexpected. A predisposition to strong cytokine secretion could not be observed, since pro-
iDCs expressed similar levels of transcripts encoding for cytokines as cDCs and monocytes. Like 
BDCA1+CD14- DCs and CD14+CD16- monocytes, pro-iDCs did not contain pre-synthesized 
Discussion 
76 
cytokines that could be released by necrotic cell death during the culture. As BDCA1+CD14int 
cells were treated in an identical way as pro-iDCs, experimental procedures such as labeling 
with CD14 and BDCA1 antibodies and general cell handling could be excluded as a trigger for 
cytokine production. A reason might be a lower tolerance to cellular stress. As flow cytometric 
cell sorting increases cellular stress and ROS production242, pro-iDCs could have an increased 
susceptibility to a ROS mediated release of cytokines. ROS in turn is detected by the NLRP3 
inflammasome and leads to the secretion of IL-1β19. Indeed, the release of IL-1β could be 
abolished by the inhibition of ROS generating enzymes and ROS neutralization. In addition, IL-
1R signaling mediated by IL-1β could be addressed as an upstream event for the release of 
further cytokines, as IL-1R blockade and IL-1β neutralization diminished levels of TNFα, IL-6, 
IL-10 and GM-CSF. Remaining levels of those cytokines might be due to incomplete blocking 
and the presence of non-neutralized IL-1α, as IL-1α binds to IL-1R as well318. Thus, an enhanced 
susceptibility to ROS may have caused NLRP3 inflammasome activation in pro-iDCs and 
enabled these cells for a rapid inflammatory response. In addition, it is possible that a 
spontaneous cytokine production and release by pro-iDCs is controlled by inhibitory signals 
present in the natural environment. As a consequence, cytokine release would no longer be 
inhibited after experimental isolation of pro-iDCs from blood. In human blood under non-
inflamed conditions, mechanisms have been revealed, which inhibit a spontaneous release of 
cytokines to prevent a possible TNFα mediated septic shock. Schäkel et al.236 demonstrated a 
CD172a dependent inhibitory mechanism for SLAN DCs. Ligation of CD47 present on 
erythrocytes to CD172a on SLAN DCs significantly inhibited the release of IL-12 and TNFα. 
Underlying mechanisms might be similar in pro-iDCs, as spontaneous release of cytokines 
could be inhibited from inflammatory DCs found in Crohns disease by the presence of a CD47 
multimer317. These cells were described as HLA-DRhiCD172ahi, which intriguingly characterize 
a group of DCs capable of spontaneous release of cytokines. These DCs include SLAN DCs, 
inflammatory DCs isolated from RA tissues170 and notably pro-iDCs as described in this work. 
We sought to investigate whether a similar anti-inflammatory mechanism in pro-iDCs could 
prevent spontaneous release of inflammatory cytokines in blood. Indeed, blood erythrocytes 
enhanced anti-inflammatory IL-10 secretion in pro-iDCs and thereby pointing to an immune 
dampening function in blood. However, the release of inflammatory cytokines was unaffected 
and possible inhibitory mechanisms remain to be elucidated.  
We found pro-iDCs to be readily capable of secreting high amounts of inflammatory cytokines, 
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and are consistently present in the blood. Hence, we speculated that they should be quickly 
responsive for recruitment into inflammatory environments where they execute their 
function. During inflammation, DCs are thought to leave the blood stream and migrate to 
inflamed tissues319. In order to home to the site of inflammation, DCs require the exposition 
to chemotactic molecules that can be detected with a number of chemokine receptors320. This 
work demonstrated that pro-iDCs expressed several chemokine receptors including CCR2 and 
CCR5. CCL2, the ligand for CCR2, was reported to be markedly elevated during inflammation 
and plays a major role in attraction of monocytes and T cells in various autoimmune diseases 
such as psoriasis, RA, asthma and uveitis321. Besides, CD14+ monocytes upregulated CCR2 
expression during atopic dermatitis and psoriasis322. Data generated from in vitro experiments 
further indicated that human monocytes and moDCs selectively migrated in response to 
CCL2323,324. In addition, CCR5 mediates leukocyte migration especially to sites of 
inflammation223,274 and pro-iDCs expressed the highest levels of CCR5 when compared to 
BDCA1+CD14- DCs. It is interesting to speculate that pro-iDCs are recruited from blood to 
inflamed tissues in a CCR2 and CCR5 dependent manner during inflammation. Interestingly, 
this work showed that BDCA1+CD14+ cells that resemble pro-iDCs were found in inflamed 
tissues such as psoriatic skin but not in skin from healthy donors.  
The release of soluble mediators by APCs has extensive effects on the activation and 
differentiation of immune cells. The secretion of IL-6 and TNFα from pro-iDCs lowered the 
activation threshold for T cells to undergo expansion and activation, which is in line with 
published observations266,267. In addition, inflammatory cytokines induced the maturation of 
blood cDCs but not pDCs, and IL-1β facilitated CD14+CD16- monocyte differentiation towards 
BDCA1+CD14+ cells. Since ROS play a central role in the induction of cytokine production in 
macrophages and DCs325,326, the ROS sensitive pro-iDCs might rapidly support immune 
responses by the release of vast amounts of inflammatory cytokines at sites of inflammation. 
This role for pro-iDCs is emphasized as stimulation with the TLR8 agonist R848 lead to the 
production of the highest amounts of IL-6 and TNFα in pro-iDCs when compared to 
BDCA1+CD14- DCs and CD14+CD16- monocytes. As this work shows, the secreted cytokines in 
turn could augment APC function and promote T cell activation. In contrast to mice, data 
showing direct implications of inflammatory DCs in disease exacerbation in vivo in humans is 
still missing. However, functional properties of pro-iDCs as shown in in vitro experiments in 
this work may indicate that the ability of pro-iDCs to readily secrete vast amounts of 
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inflammatory cytokines upon activation could further augment the presence of inflammatory 
mediators in pathogenic conditions, thereby increase the level of inflammation. This work 
demonstrated that pro-iDC derived cytokines could mature cDCs but not pDCs. In a study 
describing DCs in psoriatic and RA, isolated cDCs were characterized as mature whereas pDCs 
were immature as measured by expression levels of CD80, CD83, CD86 and CD40327. These 
markers were regulated in the same way on cDCs and pDCs treated with mediators released 
by pro-iDCs as described in this work. As pro-iDC related cells were present in both 
diseases168,170 and were described as active cytokine producers, this observation strengthens 
the hypotheses that pro-iDC related inflammatory cells may contribute in trans by cytokine 
secretion to inflammation and disease progression. Furthermore, the capacity of pro-iDCs to 
secrete high amounts of inflammatory cytokines including IL-1β, IL-6 and TNFα, and to induce 
TH17 cells could contribute to inflammation in vivo, as these cytokines and TH17 cells were 
commonly found in inflamed tissues171,328,329. As described above, this work showed that TNFα 
and IL-6 were implicated in T cell activation and proliferation. Interestingly, IL-6 was essential 
for the maintenance of T cell responses in Crohn's disease and ulcerative colitis in vivo, which 
was due to the induction of the cellular anti-apoptotic factors bcl-2 and bcl-xL330. Besides, 
IL-1β was reported to turn IFNγ producing T cells into highly inflammatory IFNγ/IL-17 
double-producers253, which are present in several autoimmune diseases254-256. Indeed, 
psoriasis is dominated by TH1 and TH17 polarized T cells171. In addition, pro-iDCs were found 
to secrete IL-23, a cytokine that enables TH17 cells to release IL-17331, and which in turn 
induces pleiotropic inflammatory responses332,333. As a consequence, neutrophils, T cells and 
APCs are recruited to and activated at the site of IL-17 secretion leading to local 
inflammation332,333. IL-17 leads to progression in psoriasis334, RA and noninfectious uveitis and 
is underlined in that IL-17 neutralization followed alleviation in severity335. Thus, pro-iDC 
related cells may be involved in several autoimmune diseases and establishment of new 
analysis methods will shed light on their implications in vivo.  
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7 Conclusion 
Inflammatory DCs were shown in a number of studies in mice to be implicated in a multitude 
of inflammatory diseases with host protective and destructive properties. These reports 
allowed a detailed description of inflammatory DCs including their cellular origin, recruitment 
to and impact at inflamed and lymphatic tissues, as well as their crucial impact during 
inflammation. Inflammatory DCs were recently identified in humans, however a 
characterization of their origin and differentiation are missing, and their biologic function is 
far away from being understood. This work demonstrated a novel human DC subset with 
inflammatory properties originating from CD14+CD16- monocytes and probable precursors of 
inflammatory DCs found in inflamed tissues. Functional data on pro-iDCs confirmed the 
immunogenic role of inflammatory DCs by the secretion of inflammatory cytokines, priming 
of TH17 responses and APC activation. First studies and data presented here may indicate a 
similar role of (pro-)inflammatory DCs in several autoimmune diseases.  In order to elucidate 
the pathogenesis of inflammatory diseases and to find medical treatments, a major objective 
is the comprehension of human moDC differentiation and recruitment in vivo. Since 
CD14+CD16- monocytes as probable precursors of (pro-)inflammatory DCs show a high 
abundance in blood and could thereby support continuous replenishment of inflammatory 
DCs, a first goal is to elucidate the role of pro-iDCs in vivo. Therefore and to interfere with a 
possible disease outcome, further understanding of factors controlling the activation and 
recruitment of pro-iDCs in vivo is required. 
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8 Appendix 
Reporter Name Reporter ID Entrez Gene ID Fold-change 
Tukey test 
p-value 
C1QB 
C1QC 
C1QA 
ENHO 
GFRA2 
FPR3 
ENHO 
SLCO2B1 
SLC38A1 
MRC1L1 
GUCY1A3 
SLC38A1 
GCOM1 
LMNA 
CLEC4F 
ABCB4 
DNASE1L3 
DKFZP564O0823 
LMNA 
LMNA 
ADD2 
CDCP1 
CTTNBP2 
A2M 
MRC2 
TIFAB 
NAV1 
SLC4A3 
FBLN2 
H19 
LOC651721 
CLEC10A 
PKIB 
PTPN13 
ITGB5 
GUCY1A3 
PLVAP 
C5orf20 
CD1E 
UBD 
LOC100128913 
STAG3 
PTPRH 
A_23_P137366 
A_23_P125977 
A_24_P222655 
A_33_P3417626 
A_33_P3317580 
A_33_P3247042 
A_33_P3405114 
A_23_P150768 
A_23_P363399 
A_23_P12746 
A_33_P3269110 
A_24_P261734 
A_33_P3423874 
A_33_P3311285 
A_23_P380990 
A_33_P3336760 
A_33_P3234202 
A_24_P191781 
A_23_P34835 
A_33_P3408762 
A_33_P3241786 
A_23_P113613 
A_23_P215744 
A_23_P116898 
A_33_P3364741 
A_33_P3380383 
A_24_P102880 
A_23_P39647 
A_23_P143981 
A_24_P52697 
A_33_P3560679 
A_23_P141505 
A_23_P145529 
A_23_P18493 
A_23_P166633 
A_23_P69573 
A_23_P56328 
A_23_P81441 
A_23_P310410 
A_23_P81898 
A_33_P3294317 
A_33_P3317058 
A_23_P101642 
713 
714 
712 
375704 
2675 
2359 
375704 
11309 
81539 
4360 
2982 
81539 
100820829 
4000 
165530 
5244 
1776 
25849 
4000 
4000 
119 
64866 
83992 
2 
9902 
497189 
89796 
6508 
2199 
283120 
100287221 
10462 
5570 
5783 
3693 
2982 
83483 
140947 
913 
10537 
10734 
5794 
140.5072 
65.1864 
47.9181 
45.5854 
35.3834 
28.6706 
27.7420 
22.4089 
22.3236 
21.4812 
20.7063 
20.5562 
18.6681 
16.3589 
16.2684 
16.2009 
15.4925 
15.4015 
15.3642 
14.8975 
14.6416 
14.5808 
14.2808 
14.1330 
13.4637 
13.4450 
13.3660 
13.1228 
13.0864 
12.1510 
11.7860 
11.5434 
11.4995 
11.4597 
11.4161 
11.2902 
11.2472 
11.0387 
10.8792 
10.7443 
10.6738 
10.0945 
9.7981 
5.90E-07 
4.67E-06 
2.87E-06 
1.71E-07 
1.73E-04 
3.76E-05 
9.71E-07 
2.52E-06 
4.46E-08 
1.30E-06 
9.33E-06 
6.47E-08 
9.96E-05 
5.75E-06 
5.72E-03 
8.32E-07 
4.80E-05 
7.86E-04 
2.59E-05 
1.56E-05 
2.08E-06 
3.49E-06 
4.92E-04 
8.00E-06 
4.54E-05 
3.11E-05 
7.29E-06 
3.67E-05 
1.95E-07 
3.63E-05 
1.36E-06 
1.25E-04 
4.15E-04 
3.15E-03 
5.67E-06 
6.23E-05 
1.71E-03 
2.94E-04 
4.68E-07 
1.52E-03 
1.29E-05 
8.94E-06 
3.64E-04 
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LHX2 
CLIC2 
P2RY6 
ARHGAP20 
CD1C 
CDCP1 
ENST00000377666 
HES4 
HLA-DOA 
CD1B 
SETBP1 
HLA-DPB2 
LAMP3 
SASH1 
SEMA7A 
S100B 
SETBP1 
GPR161 
LGMN 
RGL1 
NAV1 
PLXNA1 
SCD 
C1orf195 
GAS6 
GATM 
BLNK 
KLF12 
GPR126 
SDS 
FIGLA 
SLAMF8 
SASH1 
TREM2 
CCR5 
TNFRSF11A 
DEPDC6 
C16orf59 
FLJ14213 
UNC5B 
CD2 
P2RY14 
CD276 
RGS1 
IRF4 
CXCL9 
MSR1 
A_23_P32165 
A_33_P3775848 
A_23_P64611 
A_23_P422933 
A_33_P3273474 
A_24_P160401 
A_23_P371076 
A_33_P3342628 
A_32_P356316 
A_23_P351844 
A_32_P32413 
A_32_P505730 
A_23_P29773 
A_24_P658584 
A_23_P106389 
A_23_P143526 
A_23_P4551 
A_23_P303455 
A_23_P25994 
A_33_P3240532 
A_33_P3405068 
A_23_P57667 
A_32_P163858 
A_33_P3486059 
A_23_P146922 
A_23_P129064 
A_33_P3363637 
A_23_P354805 
A_24_P411749 
A_23_P2645 
A_33_P3315944 
A_23_P200138 
A_33_P3209279 
A_24_P12397 
A_23_P412321 
A_23_P390518 
A_23_P60166 
A_23_P26557 
A_23_P116512 
A_23_P52336 
A_23_P161076 
A_24_P165864 
A_33_P3222917 
A_23_P97141 
A_23_P214360 
A_23_P18452 
A_33_P3379326 
9355 
1193 
5031 
57569 
911 
64866 
11278 
57801 
3111 
910 
26040 
27074 
23328 
8482 
6285 
26040 
23432 
5641 
23179 
89796 
5361 
6319 
727684 
2621 
2628 
29760 
11278 
57211 
10993 
344018 
56833 
23328 
54209 
1234 
8792 
64798 
80178 
79899 
219699 
914 
9934 
80381 
5996 
3662 
4283 
4481 
9.6364 
9.4873 
9.4840 
9.4676 
9.4512 
9.4055 
9.3827 
9.2792 
9.0914 
9.0098 
8.5150 
8.2907 
8.2792 
8.1965 
7.9723 
7.9118 
7.9008 
7.8218 
7.7409 
7.7355 
7.6555 
7.6290 
7.6026 
7.5921 
7.5084 
7.4307 
7.2955 
7.2904 
7.2727 
7.1429 
7.1330 
7.1206 
7.0812 
7.0299 
6.9283 
6.9163 
6.7342 
6.6668 
6.5842 
6.5342 
6.2031 
6.1029 
6.0776 
5.9381 
5.9340 
5.7777 
5.7697 
1.88E-03 
9.52E-09 
1.64E-06 
9.42E-06 
1.86E-05 
5.65E-06 
1.04E-06 
1.69E-03 
2.93E-08 
1.32E-06 
4.26E-05 
1.09E-04 
2.76E-03 
1.44E-05 
2.42E-07 
2.27E-03 
4.13E-05 
6.74E-06 
6.14E-03 
1.62E-05 
1.36E-06 
6.76E-08 
2.45E-05 
1.88E-08 
2.09E-07 
1.88E-04 
9.94E-05 
2.94E-06 
3.91E-06 
8.98E-04 
3.44E-05 
3.08E-04 
3.57E-04 
1.09E-04 
4.11E-04 
4.90E-06 
2.72E-07 
5.32E-06 
3.30E-04 
1.75E-03 
5.59E-05 
3.26E-03 
2.35E-04 
5.09E-05 
1.66E-04 
7.20E-04 
3.63E-03 
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FAM23A 
P2RY12 
UST 
HIC1 
PPARG 
CIB2 
A_19_P00323082 
FAM190A 
APOC1 
ATP1B1 
TMEM51 
BLNK 
PPARG 
TDRKH 
DOCK1 
FAM167A 
RYR1 
HSPB1 
GUCY1B3 
MAF 
LOC729085 
CENPE 
BCL7A 
PLAU 
FAM20A 
DOK7 
TNFRSF25 
CD72 
TRH 
EBI3 
ADORA1 
MLLT4 
IL21R 
TTC7B 
PRDM1 
SLC35F2 
BATF3 
LOC399804 
MCOLN2 
ADA 
EPS8 
NDRG2 
PRDM1 
CCDC34 
SLC39A14 
MGLL 
EPB41L2 
A_33_P3382031 
A_23_P143902 
A_23_P314145 
A_23_P129856 
A_23_P252062 
A_33_P3308914 
A_19_P00323082 
A_33_P3343365 
A_24_P109214 
A_23_P62932 
A_33_P3363560 
A_24_P64344 
A_33_P3350726 
A_23_P46351 
A_23_P45059 
A_23_P334955 
A_23_P78867 
A_33_P3287646 
A_23_P121564 
A_23_P397376 
A_23_P69154 
A_23_P253524 
A_24_P203056 
A_33_P3306146 
A_32_P108254 
A_23_P398854 
A_23_P126844 
A_23_P250245 
A_23_P132760 
A_23_P119478 
A_23_P74299 
A_23_P436353 
A_24_P227927 
A_23_P25974 
A_33_P3342081 
A_23_P339098 
A_23_P160720 
A_33_P3360525 
A_23_P23639 
A_23_P210482 
A_23_P136347 
A_33_P3334515 
A_23_P350451 
A_33_P3313796 
A_23_P59950 
A_33_P3281795 
A_23_P134109 
653567 
64805 
10090 
3090 
5468 
10518 
401145 
341 
481 
55092 
29760 
5468 
11022 
1793 
83648 
6261 
3315 
2983 
4094 
729085 
1062 
605 
5328 
54757 
285489 
8718 
971 
7200 
10148 
134 
4301 
50615 
145567 
639 
54733 
55509 
255231 
100 
2059 
57447 
639 
91057 
23516 
11343 
2037 
5.7140 
5.6923 
5.6295 
5.6022 
5.5964 
5.5732 
5.4774 
5.4604 
5.4208 
5.4189 
5.2890 
5.2561 
5.2216 
5.1766 
5.1676 
5.1142 
5.0806 
5.0613 
5.0438 
5.0263 
5.0176 
5.0176 
4.8838 
4.8753 
4.7502 
4.7338 
4.6605 
4.6203 
4.5805 
4.5410 
4.4383 
4.4199 
4.3939 
4.3908 
4.3757 
4.3259 
4.2398 
4.2105 
4.2061 
4.2032 
4.1655 
4.1153 
4.1025 
4.0869 
4.0855 
4.0615 
4.0278 
2.01E-03 
9.99E-03 
9.19E-10 
2.18E-03 
1.40E-03 
1.38E-03 
1.95E-04 
1.70E-04 
2.74E-03 
2.37E-04 
9.52E-07 
1.15E-03 
1.91E-03 
1.18E-03 
2.74E-06 
1.18E-05 
2.47E-03 
1.01E-07 
4.32E-03 
1.43E-03 
1.93E-03 
4.04E-06 
3.55E-06 
5.39E-04 
8.36E-03 
5.82E-03 
2.21E-03 
4.13E-06 
6.68E-03 
5.33E-03 
4.42E-03 
1.68E-04 
1.72E-04 
3.98E-04 
4.09E-03 
7.49E-05 
6.90E-06 
8.71E-04 
4.78E-03 
4.18E-06 
1.88E-04 
2.36E-03 
4.63E-04 
1.22E-03 
3.32E-04 
2.39E-04 
8.52E-07 
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TLR10 
C10orf55 
SLC29A4 
DAB2 
ZBTB46 
NRARP 
SDC3 
AIG1 
CD79B 
ANKH 
NDRG2 
DHCR24 
SPRED1 
C3orf59 
BMP2 
SFTPD 
IL18BP 
ANKH 
HLA-DPB1 
GPR146 
PTTG1 
ZBTB46 
ADAMTS10 
AIG1 
SEZ6L 
LOC100131110 
STMN1 
CRYBB1 
HSPB1 
CHST10 
SLC46A1 
A_19_P00323081 
RUNX3 
MTSS1 
CDK6 
C6orf145 
UBE2T 
SMO 
MGLL 
OLFML2B 
AFF3 
PLA1A 
C11orf63 
SEPT8 
RUNX3 
OIP5 
CA11 
A_33_P3383970 
A_33_P3666817 
A_23_P168551 
A_33_P3338928 
A_33_P3266674 
A_33_P3337272 
A_23_P74887 
A_23_P93431 
A_23_P207201 
A_24_P303145 
A_33_P3383233 
A_23_P379475 
A_24_P107859 
A_32_P117464 
A_33_P3237150 
A_32_P107617 
A_33_P3228322 
A_24_P371628 
A_33_P3271635 
A_23_P20035 
A_23_P7636 
A_24_P592012 
A_33_P3223056 
A_33_P3416563 
A_23_P80242 
A_32_P151782 
A_33_P3317523 
A_23_P143621 
A_33_P3353242 
A_23_P102351 
A_33_P3235611 
A_19_P00323081 
A_23_P51231 
A_23_P347632 
A_24_P166663 
A_24_P272290 
A_23_P115482 
A_23_P70818 
A_24_P226008 
A_23_P137689 
A_23_P373464 
A_24_P294408 
A_23_P83751 
A_23_P415827 
A_33_P3221748 
A_23_P379614 
A_23_P78782 
81793 
414236 
222962 
1601 
140685 
441478 
9672 
51390 
974 
56172 
57447 
1718 
161742 
151963 
650 
6441 
10068 
56172 
3115 
115330 
9232 
140685 
81794 
51390 
23544 
 
3925 
1414 
3315 
9486 
113235 
 
864 
9788 
1021 
221749 
29089 
6608 
11343 
25903 
3899 
51365 
79864 
23176 
864 
11339 
770 
3.9931 
3.9834 
3.9751 
3.9627 
3.9586 
3.9408 
3.9163 
3.8704 
3.8691 
3.8530 
3.8437 
3.8357 
3.8278 
3.7711 
3.7555 
3.7503 
3.7451 
3.7373 
3.7025 
3.6782 
3.6655 
3.6364 
3.6301 
3.6276 
3.6188 
3.6150 
3.6113 
3.6050 
3.5975 
3.5851 
3.5751 
3.5665 
3.5492 
3.5345 
3.5333 
3.5101 
3.5004 
3.4955 
3.4762 
3.4762 
3.4462 
3.4176 
3.3976 
3.3799 
3.3753 
3.3543 
3.3253 
7.69E-04 
5.89E-05 
1.08E-03 
7.33E-04 
3.15E-05 
4.52E-04 
1.29E-03 
1.42E-05 
3.88E-03 
2.58E-03 
2.88E-03 
6.16E-04 
6.08E-05 
6.62E-03 
7.92E-03 
9.69E-03 
7.46E-05 
7.53E-03 
1.94E-05 
1.80E-04 
2.23E-05 
1.12E-04 
4.28E-03 
1.40E-05 
6.99E-03 
5.72E-03 
4.26E-03 
4.68E-03 
1.70E-04 
1.31E-03 
1.48E-04 
2.88E-05 
3.19E-05 
7.91E-04 
3.82E-05 
1.26E-04 
3.03E-04 
4.35E-03 
7.21E-04 
8.81E-05 
3.17E-04 
2.77E-03 
1.02E-03 
7.93E-03 
1.19E-05 
1.12E-03 
5.52E-03 
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TMEM97 
AIG1 
ATP10A 
MKL2 
HES1 
TCEA3 
CCNE1 
C1orf225 
TSPYL5 
EVL 
PYCR1 
EFNB1 
A_19_P00803836 
HLA-DQB2 
HRG 
RAPH1 
RAP2A 
ENST00000374149 
FMNL2 
CXCL12 
HLA-DPB1 
ORC6L 
RHOC 
FLJ22795 
SLAMF7 
A_33_P3329104 
STAT4 
KIAA0284 
KDELC2 
LIPA 
MTHFD1L 
CTTNBP2NL 
BCAR3 
TRAF4 
GBP1 
SORBS3 
SQLE 
CD209 
SMYD5 
MORC4 
SLC1A4 
SMC2 
OLFML2B 
KHDRBS3 
CKS1B 
IQCK 
CMAH 
A_24_P190168 
A_33_P3416574 
A_24_P215765 
A_23_P54556 
A_23_P6596 
A_23_P34375 
A_23_P209200 
A_24_P734953 
A_23_P417951 
A_23_P140427 
A_23_P130194 
A_24_P365807 
A_19_P00803836 
A_23_P19510 
A_23_P321892 
A_24_P924862 
A_24_P81965 
A_33_P3341916 
A_33_P3310552 
A_23_P202448 
A_33_P3271651 
A_23_P100344 
A_23_P406424 
A_23_P398275 
A_24_P353638 
A_33_P3329104 
A_23_P68031 
A_23_P48550 
A_33_P3214849 
A_23_P97860 
A_24_P235049 
A_23_P318420 
A_23_P97394 
A_23_P15654 
A_23_P62890 
A_33_P3409625 
A_23_P146284 
A_33_P3272493 
A_23_P91015 
A_23_P171117 
A_24_P191312 
A_33_P3357322 
A_33_P3401243 
A_33_P3332081 
A_32_P206698 
A_23_P324523 
A_33_P3281572 
27346 
51390 
57194 
57496 
3280 
6920 
898 
388610 
85453 
51466 
5831 
1947 
 
3120 
3273 
65059 
5911 
170371 
114793 
6387 
3115 
23594 
389 
388152 
57823 
 
6775 
283638 
143888 
3988 
25902 
55917 
8412 
9618 
2633 
10174 
6713 
30835 
10322 
79710 
6509 
10592 
25903 
10656 
1163 
124152 
8418 
3.3173 
3.3047 
3.2966 
3.2944 
3.2750 
3.2445 
3.2423 
3.2243 
3.2154 
3.2076 
3.1821 
3.1744 
3.1711 
3.1602 
3.1340 
3.1231 
3.1199 
3.1091 
3.0951 
3.0887 
3.0377 
3.0293 
3.0230 
3.0199 
2.9938 
2.9887 
2.9866 
2.9856 
2.9670 
2.9619 
2.9547 
2.9322 
2.9302 
2.9292 
2.9272 
2.9231 
2.9221 
2.9130 
2.9069 
2.9069 
2.9039 
2.8939 
2.8889 
2.8889 
2.8819 
2.8719 
2.8659 
5.52E-05 
1.87E-05 
2.89E-03 
4.09E-06 
9.32E-05 
2.70E-03 
1.55E-06 
1.96E-03 
7.88E-04 
3.27E-04 
1.27E-03 
2.81E-06 
2.08E-03 
1.24E-03 
4.99E-03 
8.20E-03 
8.35E-05 
4.63E-04 
3.34E-04 
2.13E-03 
2.94E-06 
6.81E-06 
8.25E-09 
4.18E-03 
1.80E-03 
1.18E-04 
7.98E-03 
9.84E-03 
2.10E-03 
1.43E-03 
1.75E-05 
1.23E-04 
6.21E-04 
4.94E-05 
7.44E-03 
6.51E-08 
1.96E-04 
8.45E-05 
8.55E-05 
1.11E-03 
8.17E-03 
1.48E-03 
6.81E-04 
3.42E-03 
2.01E-05 
4.01E-03 
1.27E-03 
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IL4I1 
FABP5 
SH3RF1 
MCM2 
FABP5 
SPATS2L 
RHEBL1 
TRIM36 
A_19_P00802810 
XYLB 
LAG3 
HLA-DPA1 
GIPC1 
SDSL 
MOBKL2B 
DLL1 
ZNF823 
ACOT7 
TUBA1B 
METTL1 
MAP4K1 
CENPP 
C3orf26 
TUBA1C 
CC2D2A 
GPATCH4 
PPM1J 
A_33_P3346533 
UACA 
CMAH 
GINS1 
HLA-DPB1 
FOXRED2 
CHEK2 
CDC25B 
CD209 
GBP4 
METTL1 
CMAH 
HLA-DQB1 
C7orf58 
AK097103 
LOC100130401 
ALKBH8 
SLC2A1 
MTHFD1L 
HSPH1 
A_33_P3405424 
A_32_P204676 
A_24_P100551 
A_32_P103633 
A_23_P59877 
A_33_P3400389 
A_33_P3264895 
A_23_P110569 
A_19_P00802810 
A_23_P212423 
A_23_P116942 
A_33_P3234277 
A_33_P3390102 
A_33_P3227472 
A_24_P32085 
A_23_P167920 
A_23_P39050 
A_24_P205589 
A_23_P128147 
A_23_P47790 
A_23_P5002 
A_33_P3245321 
A_23_P132874 
A_24_P58529 
A_23_P348383 
A_23_P97265 
A_23_P201939 
A_33_P3346533 
A_33_P3323718 
A_23_P351467 
A_33_P3340025 
A_24_P166443 
A_24_P147765 
A_23_P109452 
A_23_P210726 
A_24_P305345 
A_24_P45446 
A_33_P3700794 
A_33_P3281567 
A_33_P3424222 
A_24_P943781 
A_33_P3374398 
A_33_P3347035 
A_33_P3318357 
A_23_P571 
A_32_P135243 
A_33_P3348752 
259307 
2171 
57630 
4171 
2171 
26010 
121268 
55521 
 
9942 
3902 
3113 
10755 
113675 
79817 
28514 
55552 
11332 
10376 
4234 
11184 
401541 
84319 
84790 
57545 
54865 
333926 
 
55075 
8418 
9837 
3115 
80020 
11200 
994 
30835 
115361 
4234 
8418 
3119 
79974 
 
 
91801 
6513 
25902 
10808 
2.8659 
2.8620 
2.8461 
2.8392 
2.8284 
2.8167 
2.7876 
2.7827 
2.7779 
2.7769 
2.7359 
2.7245 
2.7245 
2.7085 
2.7048 
2.7038 
2.6973 
2.6926 
2.6870 
2.6805 
2.6749 
2.6537 
2.6500 
2.6372 
2.6308 
2.6308 
2.6217 
2.6190 
2.6153 
2.6045 
2.5982 
2.5955 
2.5937 
2.5883 
2.5847 
2.5838 
2.5767 
2.5660 
2.5633 
2.5571 
2.5535 
2.5535 
2.5509 
2.5500 
2.5438 
2.5385 
2.5385 
1.04E-04 
9.28E-05 
8.57E-03 
1.03E-06 
1.15E-04 
3.74E-08 
3.30E-06 
3.83E-04 
2.68E-05 
9.69E-04 
5.79E-03 
2.20E-06 
2.30E-05 
2.48E-03 
8.76E-04 
1.11E-05 
5.72E-06 
4.36E-05 
8.21E-05 
8.46E-05 
1.07E-04 
1.31E-03 
9.65E-05 
4.04E-07 
6.08E-03 
8.06E-04 
5.18E-06 
9.59E-03 
3.51E-03 
4.53E-04 
1.23E-03 
4.49E-06 
9.02E-05 
1.06E-05 
1.91E-03 
1.80E-05 
4.37E-03 
1.73E-04 
8.10E-05 
6.28E-03 
6.04E-03 
8.67E-03 
1.61E-03 
8.64E-03 
1.14E-03 
2.08E-05 
1.40E-09 
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FABP5 
PFAS 
XYLT1 
PLAU 
MAD2L1 
PAPSS2 
HLA-DOA 
A_19_P00801394 
C5orf4 
CKS1B 
BC038245 
C10orf2 
SDC3 
CCDC58 
TRAF4 
HLA-DRA 
ISOC2 
HSPH1 
RAB39B 
TRAF5 
USP13 
ATF7IP2 
MLLT4 
PEA15 
SEPT11 
MAP1D 
THC2680929 
UTRN 
CEP78 
HABP4 
GPAM 
THC2556327 
HLA-DPA1 
UGCG 
FAM86B2 
C6orf108 
ARL4C 
OBSL1 
PEA15 
CREBL2 
C1orf54 
GAS2L3 
BCL2 
WDHD1 
ALDH18A1 
ADAT2 
GPATCH4 
A_24_P673063 
A_23_P402610 
A_24_P787897 
A_23_P24104 
A_23_P92441 
A_24_P940166 
A_33_P3278968 
A_19_P00801394 
A_23_P501831 
A_23_P45917 
A_23_P166508 
A_23_P138461 
A_33_P3241884 
A_32_P215113 
A_33_P3402035 
A_32_P87697 
A_24_P99795 
A_23_P88119 
A_24_P408603 
A_23_P201731 
A_23_P40989 
A_23_P129466 
A_33_P3278407 
A_33_P3220827 
A_33_P3310475 
A_23_P90790 
A_33_P3397910 
A_33_P3234855 
A_33_P3219641 
A_33_P3592015 
A_24_P227069 
A_33_P3271634 
A_23_P30913 
A_23_P313389 
A_33_P3269740 
A_33_P3372451 
A_33_P3323722 
A_23_P300484 
A_24_P410952 
A_24_P56194 
A_23_P74778 
A_32_P189204 
A_23_P352266 
A_23_P25873 
A_23_P1361 
A_33_P3268798 
A_33_P3211263 
2171 
5198 
64131 
5328 
4085 
9060 
3111 
 
10826 
1163 
 
56652 
9672 
131076 
9618 
3122 
79763 
10808 
116442 
7188 
8975 
80063 
4301 
8682 
55752 
254042 
 
7402 
84131 
22927 
57678 
3115 
3113 
7357 
653333 
10591 
10123 
23363 
8682 
1389 
79630 
283431 
596 
11169 
5832 
134637 
54865 
2.5315 
2.5193 
2.5140 
2.4889 
2.4751 
2.4734 
2.4572 
2.4504 
2.4470 
2.4444 
2.4394 
2.4385 
2.4284 
2.4275 
2.4259 
2.4233 
2.4200 
2.4175 
2.4099 
2.4058 
2.3991 
2.3958 
2.3958 
2.3875 
2.3867 
2.3759 
2.3644 
2.3620 
2.3563 
2.3530 
2.3457 
2.3440 
2.3440 
2.3416 
2.3206 
2.3198 
2.3070 
2.3054 
2.2974 
2.2942 
2.2934 
2.2934 
2.2871 
2.2784 
2.2728 
2.2650 
2.2618 
4.62E-04 
7.52E-04 
5.87E-04 
3.24E-03 
7.14E-04 
2.46E-03 
1.08E-04 
1.16E-03 
1.74E-03 
2.97E-07 
2.29E-03 
4.59E-03 
3.76E-03 
3.20E-04 
2.45E-06 
6.22E-04 
1.97E-04 
2.32E-07 
1.18E-03 
1.44E-03 
1.12E-03 
1.74E-04 
6.58E-04 
4.62E-06 
1.23E-03 
2.12E-03 
4.19E-06 
2.80E-03 
7.31E-06 
5.13E-05 
2.05E-03 
2.49E-05 
9.71E-07 
1.16E-03 
7.28E-04 
2.77E-03 
8.72E-04 
1.78E-04 
5.71E-06 
2.44E-04 
1.59E-04 
1.09E-03 
8.17E-03 
3.23E-03 
4.00E-03 
8.27E-05 
9.05E-03 
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HDGFRP3 
C6orf66 
BCKDHB 
RICS 
HSPA8 
PTTG2 
CD74 
ZNF329 
NRP2 
PTGER4 
SGPP1 
PPARGC1B 
PID1 
MCM6 
ULK2 
CIITA 
GOT1 
GINS4 
CBLN3 
FMNL2 
CCL17 
VEGFB 
UTRN 
ACSF2 
ABI2 
UTRN 
PAOX 
SNORA55 
HLA-DRB1 
ZFP82 
HAUS5 
SLIT1 
LOC100128994 
SACS 
DST 
NPM3 
BAG2 
PAOX 
NME1 
HTR7 
HSD17B8 
FARP2 
GAMT 
AI669688 
LOC653390 
PMVK 
BC035371 
A_23_P344451 
A_24_P171983 
A_24_P914513 
A_23_P161686 
A_33_P3390758 
A_23_P18579 
A_23_P70095 
A_23_P413634 
A_33_P3297415 
A_23_P148047 
A_23_P347048 
A_23_P213959 
A_23_P21485 
A_23_P90612 
A_23_P55107 
A_32_P209960 
A_23_P63825 
A_33_P3340040 
A_33_P3412900 
A_32_P193080 
A_23_P26325 
A_23_P1594 
A_32_P524014 
A_23_P4190 
A_24_P933418 
A_33_P3234864 
A_33_P3336387 
A_33_P3648417 
A_24_P343233 
A_23_P416813 
A_33_P3269338 
A_33_P3411035 
A_33_P3265872 
A_33_P3405500 
A_23_P303718 
A_23_P52298 
A_23_P356554 
A_23_P385771 
A_23_P152804 
A_23_P500381 
A_23_P81973 
A_33_P3350728 
A_24_P19228 
A_33_P3367077 
A_24_P475864 
A_23_P114774 
A_24_P376422 
50810 
29078 
594 
9743 
3312 
10744 
972 
79673 
8828 
5734 
81537 
133522 
55022 
4175 
9706 
4261 
2805 
84296 
643866 
114793 
6361 
7423 
7402 
80221 
10152 
7402 
196743 
677834 
3123 
284406 
23354 
6585 
 
26278 
667 
10360 
9532 
196743 
4830 
3363 
7923 
9855 
2593 
 
653390 
10654 
 
2.2603 
2.2595 
2.2408 
2.2384 
2.2353 
2.2245 
2.2245 
2.2046 
2.2046 
2.2030 
2.2015 
2.1969 
2.1962 
2.1931 
2.1901 
2.1833 
2.1765 
2.1750 
2.1675 
2.1644 
2.1622 
2.1592 
2.1570 
2.1517 
2.1495 
2.1428 
2.1421 
2.1287 
2.1287 
2.1258 
2.1251 
2.1184 
2.1177 
2.1177 
2.1148 
2.1126 
2.1104 
2.1104 
2.1038 
2.0980 
2.0951 
2.0936 
2.0929 
2.0929 
2.0770 
2.0763 
2.0712 
4.69E-03 
4.15E-06 
9.96E-03 
3.01E-03 
4.84E-04 
9.69E-04 
1.45E-04 
6.34E-03 
9.88E-03 
4.55E-05 
7.97E-04 
4.56E-04 
1.46E-03 
4.32E-04 
1.68E-05 
5.54E-05 
1.07E-04 
1.90E-04 
2.60E-03 
6.53E-04 
3.58E-04 
1.65E-04 
8.83E-04 
3.41E-08 
8.11E-05 
8.03E-03 
1.25E-05 
1.19E-03 
2.21E-03 
8.75E-03 
5.67E-04 
1.08E-04 
9.92E-04 
4.77E-04 
5.74E-03 
2.51E-05 
2.06E-03 
2.52E-05 
1.45E-03 
1.81E-04 
1.60E-03 
7.65E-03 
2.73E-03 
2.14E-03 
9.65E-03 
7.85E-06 
5.20E-03 
 Appendix 
 
88 
CR604707 
PPARGC1B 
OSBPL3 
PAICS 
EARS2 
RPL39L 
MOV10 
KCNK13 
C2orf7 
MCM4 
MTHFD1L 
HIG2 
FDX1L 
TTC27 
PCCA 
LRRC34 
ASAP3 
RFC4 
S1PR2 
CTNND1 
C2orf43 
A_19_P00327972 
ATF5 
HLA-DMA 
IMPDH2 
FMNL3 
 
A_32_P2634 
A_33_P3816688 
A_24_P377499 
A_24_P200427 
A_23_P152353 
A_23_P29594 
A_23_P161125 
A_23_P3177 
A_23_P131596 
A_23_P370989 
A_23_P214907 
A_23_P20022 
A_24_P416660 
A_23_P131227 
A_23_P48358 
A_23_P41194 
A_23_P114689 
A_23_P18196 
A_32_P827528 
A_23_P251316 
A_23_P420256 
A_19_P00327972 
A_23_P119337 
A_24_P50245 
A_33_P3214298 
A_33_P3415923 
 
 
133522 
26031 
10606 
124454 
116832 
4343 
56659 
84279 
4173 
25902 
29923 
112812 
55622 
5095 
151827 
55616 
5984 
9294 
1500 
60526 
 
22809 
3108 
3615 
91010 
 
2.0698 
2.0691 
2.0662 
2.0648 
2.0584 
2.0569 
2.0548 
2.0484 
2.0477 
2.0477 
2.0470 
2.0463 
2.0420 
2.0413 
2.0371 
2.0335 
2.0314 
2.0314 
2.0314 
2.0279 
2.0258 
2.0237 
2.0230 
2.0223 
2.0118 
2.0062 
 
4.13E-03 
2.79E-03 
1.09E-04 
2.07E-05 
3.06E-04 
9.46E-04 
3.06E-05 
2.48E-04 
1.97E-03 
2.15E-03 
1.41E-03 
7.59E-03 
1.10E-05 
2.98E-04 
9.79E-04 
3.10E-03 
1.27E-03 
1.09E-07 
2.66E-03 
1.88E-04 
3.29E-03 
1.43E-04 
1.73E-03 
1.21E-04 
4.38E-04 
3.89E-04 
 
Table 3 Agilent reporters with an at least two-fold upregulation in BDCA1+CD14+ pro-iDCs relative to CD14+ CD16- 
monocytes (Tukey test p-value ≤ 0.05). 
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Reporter Name Reporter ID Entrez Gene ID Fold-change 
Tukey test      
p-value 
S100P 
BPI 
ANXA8L2 
BPI 
HP 
VNN3 
DAPK2 
TPST1 
PADI4 
SLCO4C1 
LOC392382 
F5 
TNFΑIP6 
VNN2 
LOC572558 
CXCL1 
S1PR3 
MCTP2 
HPR 
FAM82A1 
LOC732146 
SERPINB2 
APCDD1 
CYP1B1 
MCTP2 
AQP9 
SERPINB10 
PDE6H 
C9orf47 
TDRD9 
RPH3A 
CMTM2 
STEAP4 
MGAM 
ALOX5AP 
MOSC1 
KCNJ15 
PRRT4 
C9orf47 
DYSF 
A_19_P00322955 
MOSC1 
TSPAN2 
ALDH1A1 
CES1 
A_23_P58266 
A_23_P131785 
A_32_P105549 
A_23_P131789 
A_23_P206760 
A_23_P398449 
A_24_P10233 
A_23_P145965 
A_23_P138262 
A_32_P154342 
A_24_P255384 
A_32_P41604 
A_23_P165624 
A_23_P122724 
A_32_P157208 
A_23_P7144 
A_33_P3281283 
A_24_P244944 
A_33_P3289236 
A_23_P209625 
A_33_P3277367 
A_24_P245379 
A_23_P337262 
A_33_P3290343 
A_23_P65789 
A_23_P106362 
A_23_P313981 
A_23_P64913 
A_33_P3379061 
A_32_P208350 
A_23_P76234 
A_23_P152234 
A_33_P3555937 
A_23_P42897 
A_24_P347378 
A_33_P3247205 
A_33_P3376140 
A_33_P3407529 
A_33_P3248638 
A_23_P39931 
A_19_P00322955 
A_33_P3293362 
A_24_P62659 
A_23_P83098 
A_33_P3241269 
6286 
671 
244 
671 
3240 
55350 
23604 
8460 
23569 
353189 
 
2153 
7130 
8875 
572558 
2919 
1903 
55784 
3250 
1545 
 
5055 
147495 
1545 
55784 
366 
5273 
5149 
286223 
122402 
22895 
146225 
79689 
8972 
241 
64757 
3772 
401399 
286223 
8291 
 
64757 
10100 
216 
1066 
52.201 
43.850 
32.447 
27.974 
25.510 
23.802 
23.377 
23.103 
22.093 
21.496 
19.400 
18.501 
17.741 
17.539 
17.220 
16.359 
15.450 
13.642 
13.595 
12.197 
12.021 
11.975 
11.696 
11.692 
11.416 
11.236 
11.216 
10.422 
10.407 
10.378 
10.307 
10.289 
9.866 
9.687 
9.616 
9.590 
9.517 
9.445 
9.177 
9.091 
8.843 
8.806 
8.601 
8.553 
8.477 
5.73E-05 
2.95E-06 
6.80E-05 
2.39E-04 
6.85E-09 
5.15E-10 
2.80E-06 
3.03E-06 
9.15E-10 
2.28E-05 
4.47E-08 
9.22E-13 
7.08E-08 
2.70E-06 
4.46E-06 
1.20E-04 
2.08E-04 
1.48E-07 
2.63E-06 
1.23E-03 
4.67E-03 
9.60E-09 
1.14E-03 
1.11E-03 
6.00E-06 
4.74E-04 
2.60E-09 
3.31E-05 
2.80E-06 
1.27E-03 
3.81E-07 
2.98E-05 
4.55E-08 
9.71E-08 
1.63E-04 
2.79E-06 
4.01E-07 
4.95E-06 
4.23E-09 
1.39E-03 
2.67E-06 
9.59E-07 
3.25E-06 
1.65E-05 
6.37E-03 
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CRISPLD2 
PANX2 
LGALS12 
ADAMTS5 
AKR1C3 
A_19_P00809432 
PRL 
SYNE1 
ADAM19 
ZBTB16 
C2orf39 
SELL 
S100A12 
ENST00000442512 
AFF2 
CES1 
LRRC4 
KRT23 
SPRY1 
ALDH1A1 
CES1 
LOC100128276 
HAL 
STEAP4 
A_19_P00316135 
S100A12 
STX1A 
A_19_P00804329 
ANKRD18A 
CR1 
CYP4F3 
HTRA1 
SELP 
A_19_P00332072 
TNFSF14 
CXCL1 
KRT23 
SPINK8 
C9orf47 
MAPK13 
PRLR 
DGAT2 
GPR177 
PNPLA1 
KCNJ15 
KIAA1257 
TMEM38A 
A_23_P106602 
A_33_P3588134 
A_23_P139198 
A_33_P3372426 
A_23_P138541 
A_19_P00809432 
A_32_P65616 
A_33_P3335910 
A_23_P81369 
A_23_P104804 
A_23_P308722 
A_33_P3400273 
A_33_P3385785 
A_33_P3283964 
A_33_P3293888 
A_33_P3389704 
A_33_P3263217 
A_33_P3299761 
A_23_P144476 
A_33_P3379644 
A_23_P206733 
A_33_P3326447 
A_23_P61637 
A_33_P3318322 
A_19_P00316135 
A_23_P74001 
A_23_P168556 
A_19_P00804329 
A_33_P3238941 
A_23_P256821 
A_33_P3294277 
A_23_P97990 
A_23_P137697 
A_19_P00332072 
A_24_P237036 
A_33_P3330264 
A_23_P78248 
A_33_P3258542 
A_24_P316601 
A_24_P406132 
A_33_P3416757 
A_23_P53198 
A_24_P256380 
A_32_P526255 
A_33_P3267532 
A_32_P163739 
A_23_P101392 
83716 
56666 
85329 
11096 
8644 
 
5617 
23345 
8728 
7704 
92749 
6402 
6283 
390732 
2334 
1066 
64101 
25984 
10252 
216 
1066 
100508384 
3034 
79689 
 
6283 
6804 
 
253650 
1378 
4051 
5654 
6403 
 
8740 
2919 
25984 
646424 
286223 
5603 
5618 
84649 
79971 
285848 
3772 
57501 
79041 
8.444 
8.401 
8.188 
8.114 
8.109 
8.086 
7.887 
7.563 
7.519 
7.480 
7.298 
7.288 
7.280 
7.160 
6.921 
6.842 
6.840 
6.795 
6.641 
6.632 
6.573 
6.536 
6.338 
6.296 
6.251 
6.114 
6.078 
5.973 
5.965 
5.918 
5.864 
5.820 
5.788 
5.768 
5.706 
5.589 
5.523 
5.476 
5.428 
5.421 
5.411 
5.389 
5.354 
5.322 
5.289 
5.287 
5.263 
3.65E-04 
2.03E-08 
1.79E-03 
6.09E-06 
4.68E-04 
4.01E-03 
3.56E-06 
6.54E-05 
4.56E-03 
5.34E-07 
6.39E-04 
7.67E-06 
1.54E-05 
2.00E-04 
2.74E-05 
6.30E-03 
7.86E-04 
1.22E-04 
4.17E-04 
1.73E-06 
1.88E-04 
1.13E-04 
5.16E-05 
1.71E-04 
9.57E-05 
3.57E-03 
9.50E-05 
2.91E-03 
8.57E-05 
5.32E-03 
8.35E-04 
6.79E-04 
1.21E-05 
1.07E-03 
1.99E-03 
2.83E-04 
2.23E-04 
1.86E-04 
2.31E-03 
1.42E-04 
5.63E-04 
1.86E-04 
2.86E-04 
7.28E-05 
6.68E-04 
4.47E-05 
8.67E-07 
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CDH26 
CLTCL1 
CETP 
CLEC4D 
PADI2 
ADAM19 
A_19_P00317277 
CLEC4D 
ST6GALNAC3 
A_19_P00321148 
TREML3 
RGL4 
LRRC6 
SPOCK1 
NFE2 
RPH3A 
ABCC6 
RILPL1 
LOC100131892 
PRLR 
A_19_P00316185 
SERINC2 
CLEC4E 
A_19_P00322394 
FRY 
A_19_P00801649 
A_19_P00801354 
TOX2 
TREM1 
LOC389634 
ZFYVE28 
A_19_P00807643 
LOC646626 
ZFYVE28 
F12 
CTH 
SEMA3C 
PADI2 
A_19_P00318057 
LOC151438 
AX721082 
A_19_P00331762 
LOC100128668 
ELOVL3 
C1orf226 
C8orf46 
A_19_P00321593 
A_23_P502957 
A_23_P143559 
A_23_P49376 
A_33_P3258977 
A_23_P201747 
A_23_P374082 
A_19_P00317277 
A_33_P3352578 
A_33_P3275055 
A_19_P00321148 
A_24_P170439 
A_23_P306941 
A_23_P112004 
A_24_P354689 
A_23_P13753 
A_33_P3395384 
A_23_P100539 
A_23_P169934 
A_33_P3384427 
A_23_P167468 
A_19_P00316185 
A_24_P145629 
A_33_P3318509 
A_19_P00322394 
A_33_P3223495 
A_19_P00801649 
A_19_P00801354 
A_23_P154566 
A_33_P3319905 
A_32_P221305 
A_33_P3277579 
A_19_P00807643 
A_32_P703 
A_32_P104746 
A_33_P3233871 
A_23_P126103 
A_23_P256473 
A_24_P187970 
A_19_P00318057 
A_33_P3479449 
A_33_P3251198 
A_19_P00331762 
A_33_P3415653 
A_23_P149858 
A_23_P103511 
A_23_P353614 
A_19_P00321593 
60437 
8218 
1071 
338339 
11240 
8728 
 
338339 
256435 
 
340206 
266747 
23639 
6695 
4778 
22895 
368 
353116 
 
5618 
 
347735 
26253 
 
10129 
 
 
84969 
54210 
389634 
57732 
 
646626 
57732 
2161 
1491 
10512 
11240 
 
100506328 
23236 
 
100128668 
83401 
400793 
254778 
 
5.231 
5.202 
5.175 
5.135 
5.042 
4.966 
4.938 
4.902 
4.885 
4.754 
4.727 
4.713 
4.640 
4.640 
4.633 
4.633 
4.580 
4.568 
4.555 
4.535 
4.491 
4.488 
4.458 
4.409 
4.376 
4.364 
4.342 
4.333 
4.305 
4.292 
4.280 
4.218 
4.211 
4.206 
4.102 
4.101 
4.061 
4.054 
4.040 
4.025 
4.017 
4.007 
3.916 
3.908 
3.889 
3.883 
3.858 
1.55E-04 
1.24E-05 
7.52E-03 
1.52E-05 
6.82E-04 
4.42E-03 
2.75E-03 
3.41E-06 
1.68E-03 
2.47E-03 
6.43E-03 
1.85E-05 
1.60E-03 
9.00E-04 
3.10E-03 
2.06E-05 
9.20E-06 
4.53E-03 
2.03E-04 
1.65E-05 
3.04E-06 
3.04E-03 
1.05E-03 
1.13E-03 
1.12E-03 
5.42E-03 
1.66E-05 
6.66E-03 
1.56E-05 
9.20E-03 
2.05E-03 
4.48E-03 
4.26E-04 
4.89E-05 
2.98E-03 
2.03E-03 
5.63E-04 
1.83E-03 
3.18E-04 
1.50E-03 
2.44E-04 
7.91E-05 
9.82E-03 
4.84E-04 
5.03E-03 
5.78E-05 
1.28E-05 
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VCAN 
CPAMD8 
LAMC1 
A_19_P00318551 
A_19_P00321594 
A_19_P00316518 
LIN7A 
IRS2 
WLS 
ZNF697 
BASP1 
SLC22A1 
SLC2A14 
SLC2A3 
A_33_P3304748 
ENST00000229824 
ADM 
DKFZp313P036 
LOC497257 
RNU4ATAC 
ENST00000340798 
ATP2A3 
A_19_P00317616 
C17orf76 
MPP7 
NOL3 
ENST00000401931 
RNU105B 
ENST00000400513 
MAP2K6 
TMEM144 
LOC402778 
PLCB1 
OR7E140P 
MT1F 
SYCP2 
NEK8 
ARHGAP24 
LOC389634 
A_33_P3279311 
A_19_P00326336 
A_33_P3333327 
A_33_P3400023 
A_33_P3262074 
PRR7 
UNQ9368 
MREG 
A_23_P144959 
A_23_P67198 
A_23_P201628 
A_19_P00318551 
A_19_P00321594 
A_19_P00316518 
A_23_P99253 
A_24_P154037 
A_33_P3311551 
A_32_P19716 
A_23_P213385 
A_23_P145569 
A_32_P47754 
A_23_P139669 
A_33_P3304748 
A_33_P3424328 
A_23_P127948 
A_24_P221968 
A_32_P219148 
A_33_P3839897 
A_33_P3383762 
A_23_P207632 
A_19_P00317616 
A_23_P368484 
A_33_P3229477 
A_23_P206371 
A_33_P3243230 
A_33_P3399534 
A_33_P3223487 
A_23_P207445 
A_33_P3304372 
A_33_P3358601 
A_23_P6099 
A_33_P3211793 
A_23_P15174 
A_23_P210675 
A_24_P99639 
A_33_P3236030 
A_33_P3243500 
A_33_P3279311 
A_19_P00326336 
A_33_P3333327 
A_33_P3400023 
A_33_P3262074 
A_33_P3319780 
A_24_P927716 
A_23_P108948 
1462 
27151 
3915 
 
 
 
8825 
8660 
79971 
90874 
10409 
6580 
144195 
6515 
 
401258 
133 
643802 
497257 
100151683 
 
489 
 
388341 
143098 
8996 
3576 
26767 
10129 
5608 
55314 
402778 
23236 
 
4494 
10388 
284086 
83478 
 
 
 
 
 
 
80758 
643036 
55686 
3.849 
3.834 
3.818 
3.804 
3.780 
3.774 
3.770 
3.749 
3.731 
3.724 
3.690 
3.658 
3.640 
3.600 
3.578 
3.566 
3.566 
3.555 
3.516 
3.510 
3.510 
3.463 
3.427 
3.396 
3.389 
3.383 
3.350 
3.344 
3.330 
3.277 
3.275 
3.273 
3.257 
3.252 
3.252 
3.233 
3.228 
3.220 
3.211 
3.202 
3.194 
3.172 
3.148 
3.134 
3.106 
3.088 
3.088 
1.55E-03 
2.57E-05 
8.64E-03 
2.08E-04 
3.10E-03 
4.79E-04 
7.58E-07 
9.48E-06 
8.32E-05 
3.03E-03 
3.98E-04 
6.36E-04 
3.60E-03 
3.02E-03 
5.65E-06 
1.48E-03 
1.53E-06 
2.48E-03 
1.52E-03 
3.09E-03 
7.47E-06 
1.72E-05 
6.75E-04 
1.59E-03 
2.24E-03 
8.27E-06 
5.34E-03 
1.02E-03 
1.16E-04 
3.01E-08 
7.29E-03 
4.60E-03 
9.10E-04 
1.58E-03 
1.73E-03 
9.70E-03 
1.04E-03 
7.36E-03 
4.29E-03 
4.68E-04 
6.04E-05 
3.80E-03 
5.76E-03 
6.11E-03 
4.89E-06 
2.33E-03 
3.10E-03 
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PGM5 
DYSFIP1 
TMEM170B 
A_33_P3615955 
ORM2 
HSPA1L 
ENST00000338061 
LOC257358 
SSPO 
THC2715267 
LOC647121 
FRY 
JAG1 
LOC389634 
LOC389634 
LOC389634 
LOC399744 
SLC11A1 
DDEF1IT1 
RNASE2 
RNASE3 
TXNDC3 
LOC100129186 
AIM2 
RAB27A 
TMEM170B 
LRP3 
PLAUR 
HLX 
DKFZp547G183 
FLJ22662 
MGST1 
TSHZ3 
FMO5 
FXYD6 
A_33_P3229037 
DKFZp761E198 
PECR 
EGR1 
ABHD5 
A_33_P3304081 
OMG 
ACPL2 
LOC644727 
FRY 
MGC13005 
A_19_P00807435 
A_24_P254949 
A_33_P3287472 
A_32_P178966 
A_33_P3615955 
A_23_P9485 
A_23_P70547 
A_33_P3251193 
A_32_P23308 
A_33_P3277173 
A_33_P3308219 
A_24_P684186 
A_33_P3223497 
A_23_P210763 
A_33_P3243502 
A_33_P3364651 
A_33_P3365553 
A_33_P3369213 
A_33_P3317009 
A_23_P146325 
A_23_P151637 
A_23_P163025 
A_23_P259611 
A_33_P3342967 
A_32_P44394 
A_24_P373174 
A_33_P3352278 
A_33_P3212188 
A_23_P16469 
A_23_P126266 
A_33_P3732466 
A_23_P87709 
A_23_P36658 
A_23_P361014 
A_33_P3376214 
A_23_P150394 
A_33_P3229037 
A_24_P9883 
A_23_P91140 
A_23_P214080 
A_23_P250294 
A_33_P3304081 
A_23_P55286 
A_23_P57760 
A_33_P3289251 
A_33_P3223488 
A_32_P227317 
A_19_P00807435 
5239 
116729 
100113407 
 
5005 
3305 
23236 
257358 
 
 
133418 
10129 
182 
389634 
 
389634 
399744 
6556 
29065 
6036 
6037 
51314 
100129186 
9447 
5873 
100113407 
4037 
5329 
3142 
55525 
79887 
4257 
57616 
2330 
53826 
 
91056 
55825 
1958 
51099 
 
4974 
92370 
644727 
10129 
84771 
 
3.085 
3.082 
3.080 
3.069 
3.054 
3.020 
3.015 
3.006 
2.997 
2.992 
2.969 
2.951 
2.935 
2.919 
2.910 
2.896 
2.883 
2.882 
2.876 
2.867 
2.852 
2.851 
2.828 
2.826 
2.813 
2.792 
2.739 
2.733 
2.729 
2.728 
2.713 
2.693 
2.672 
2.671 
2.664 
2.664 
2.660 
2.658 
2.656 
2.655 
2.652 
2.641 
2.627 
2.609 
2.604 
2.595 
2.588 
2.61E-03 
1.25E-05 
8.41E-05 
5.10E-03 
8.90E-04 
1.24E-04 
1.59E-05 
1.05E-03 
5.68E-03 
3.45E-04 
2.08E-04 
1.89E-05 
2.04E-03 
2.06E-03 
1.76E-03 
9.50E-04 
2.80E-05 
5.59E-04 
6.80E-03 
1.89E-04 
4.79E-03 
3.88E-03 
2.52E-04 
3.92E-04 
2.01E-07 
5.47E-05 
1.50E-04 
6.98E-03 
1.44E-04 
1.43E-04 
7.26E-04 
2.33E-05 
2.08E-03 
8.10E-04 
6.51E-04 
3.43E-03 
6.06E-03 
2.20E-03 
7.07E-03 
1.93E-05 
1.23E-04 
3.26E-03 
1.19E-03 
5.08E-05 
4.56E-05 
1.69E-04 
9.30E-04 
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SAG 
LOC399744 
tcag7.907 
tcag7.907 
RNF24 
ABCC6 
A_19_P00802450 
KIF13A 
AMPH 
CSF3R 
SNX21 
A_19_P00803229 
AK097080 
ACSL1 
ATP2A3 
ABCC6 
AK126778 
FBXL16 
TREML2 
A_19_P00322101 
PTPRN2 
SPATA13 
IGF2R 
AK125099 
LOC441268 
PCSK5 
LOC401357 
A_33_P3221055 
ADAM8 
SNX21 
FLJ45445 
A_19_P00328825 
BAG4 
tcag7.907 
FAM151B 
A_19_P00322727 
LOC100291714 
MTMR3 
PTPLA 
EPHX1 
FLJ45445 
A_33_P3390673 
TRIM7 
DKFZp434F142 
LOC100133331 
A_19_P00322493 
A_19_P00323307 
A_23_P5853 
A_33_P3248252 
A_33_P3362397 
A_32_P75425 
A_24_P333019 
A_23_P15272 
A_19_P00802450 
A_33_P3242659 
A_23_P31273 
A_33_P3881262 
A_24_P318897 
A_19_P00803229 
A_24_P818010 
A_23_P110212 
A_24_P202319 
A_33_P3298043 
A_33_P3373203 
A_23_P406385 
A_24_P214858 
A_19_P00322101 
A_32_P79434 
A_33_P3298105 
A_23_P334021 
A_32_P190461 
A_33_P3415648 
A_23_P257003 
A_24_P659122 
A_33_P3221055 
A_24_P300777 
A_23_P154585 
A_33_P3238777 
A_19_P00328825 
A_24_P930926 
A_32_P11230 
A_33_P3728979 
A_19_P00322727 
A_33_P3423565 
A_33_P3235335 
A_33_P3235410 
A_23_P34537 
A_33_P3225873 
A_33_P3390673 
A_24_P277615 
A_23_P111797 
A_33_P3287883 
A_19_P00322493 
A_19_P00323307 
6295 
399744 
402483 
401149 
11237 
368 
 
63971 
273 
1441 
90203 
 
100133161 
2180 
489 
368 
 
146330 
79865 
 
5799 
221178 
3482 
 
 
5125 
401357 
 
101 
90203 
399844 
 
9530 
399744 
167555 
 
 
8897 
9200 
2052 
399844 
 
81786 
84214 
100133331 
 
 
2.585 
2.581 
2.579 
2.536 
2.529 
2.506 
2.502 
2.501 
2.498 
2.498 
2.488 
2.486 
2.474 
2.461 
2.450 
2.445 
2.436 
2.421 
2.417 
2.407 
2.404 
2.400 
2.399 
2.398 
2.398 
2.384 
2.383 
2.376 
2.376 
2.373 
2.363 
2.357 
2.354 
2.347 
2.347 
2.345 
2.342 
2.338 
2.334 
2.321 
2.320 
2.320 
2.316 
2.313 
2.310 
2.309 
2.309 
9.19E-03 
1.54E-04 
8.91E-03 
2.27E-03 
8.07E-05 
1.95E-03 
2.84E-03 
3.32E-05 
1.36E-03 
5.29E-03 
2.11E-03 
2.47E-04 
5.89E-04 
4.83E-04 
6.67E-06 
1.27E-03 
3.80E-03 
1.39E-03 
6.75E-05 
1.13E-03 
3.01E-03 
3.37E-03 
1.19E-03 
2.31E-04 
6.34E-05 
2.58E-04 
6.74E-04 
4.76E-05 
4.85E-05 
2.60E-03 
1.35E-04 
6.24E-04 
7.32E-03 
2.12E-05 
2.87E-03 
7.22E-06 
5.87E-04 
7.43E-09 
4.47E-03 
3.11E-04 
8.35E-03 
8.92E-04 
9.01E-04 
1.01E-05 
8.84E-06 
5.33E-05 
4.90E-03 
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IL31RA 
ALOX15B 
PRRG4 
IVNS1ABP 
TRIM7 
AOC3 
ROPN1L 
LOC731275 
FRY 
ULK1 
MXD1 
ICAM3 
FLJ45445 
LOC100132217 
A_33_P3292126 
LOC100132217 
SCCPDH 
A_19_P00318861 
A_19_P00329574 
LOC731275 
LOC731275 
A_19_P00316995 
A_19_P00316010 
A_19_P00320602 
LOC349114 
MTMR3 
METTL9 
LOC729218 
tcag7.907 
PGD 
SLC22A4 
LOC349114 
SPATA13 
THC2677526 
THC2656683 
LMTK2 
A_19_P00811179 
ENST00000366583 
RAB37 
MSL1 
EMB 
AK097701 
THC2764236 
LOC100133060 
A_19_P00319069 
LOC729603 
A_19_P00802874 
A_33_P3691168 
A_23_P60627 
A_23_P127663 
A_33_P3280875 
A_23_P30315 
A_23_P426305 
A_23_P121885 
A_33_P3226380 
A_23_P105862 
A_24_P73370 
A_23_P408094 
A_23_P164691 
A_33_P3248900 
A_33_P3362249 
A_33_P3292126 
A_33_P3308101 
A_23_P62807 
A_19_P00318861 
A_19_P00329574 
A_24_P691775 
A_33_P3229380 
A_19_P00316995 
A_19_P00316010 
A_19_P00320602 
A_33_P3268629 
A_33_P3235330 
A_24_P202139 
A_33_P3256088 
A_24_P586390 
A_23_P126623 
A_23_P156180 
A_33_P3365747 
A_23_P390116 
A_33_P3380236 
A_33_P3268910 
A_33_P3266923 
A_19_P00811179 
A_33_P3349883 
A_33_P3314594 
A_33_P3356341 
A_33_P3359900 
A_33_P3220425 
A_33_P3360867 
A_33_P3249731 
A_19_P00319069 
A_33_P3410859 
A_19_P00802874 
133396 
247 
79056 
10625 
81786 
8639 
83853 
731275 
10129 
8408 
4084 
3385 
399844 
100288292 
 
401357 
51097 
 
 
401149 
731275 
 
 
 
349114 
8897 
51108 
401149 
100133331 
5226 
6583 
349114 
221178 
 
10252 
22853 
 
3964 
326624 
339287 
133418 
 
 
 
 
729603 
 
2.309 
2.307 
2.302 
2.297 
2.293 
2.290 
2.289 
2.284 
2.282 
2.281 
2.276 
2.274 
2.270 
2.268 
2.265 
2.259 
2.254 
2.249 
2.244 
2.236 
2.234 
2.233 
2.232 
2.215 
2.215 
2.214 
2.210 
2.209 
2.205 
2.205 
2.202 
2.199 
2.192 
2.188 
2.185 
2.176 
2.173 
2.173 
2.172 
2.170 
2.167 
2.166 
2.164 
2.163 
2.162 
2.159 
2.156 
1.65E-03 
3.58E-03 
4.35E-04 
1.51E-04 
2.64E-03 
3.75E-03 
1.80E-05 
1.73E-04 
1.75E-04 
1.12E-06 
5.20E-03 
4.54E-03 
2.88E-05 
5.29E-05 
1.58E-05 
8.36E-07 
2.42E-03 
3.56E-05 
3.06E-03 
1.31E-04 
4.59E-04 
6.54E-03 
4.63E-03 
9.38E-03 
6.06E-06 
6.05E-04 
3.97E-05 
4.58E-05 
4.75E-06 
2.11E-04 
7.80E-04 
6.02E-05 
3.06E-03 
4.71E-03 
3.80E-03 
4.25E-03 
1.44E-03 
3.49E-03 
5.63E-03 
1.01E-06 
2.06E-03 
3.10E-03 
1.82E-05 
4.14E-04 
6.61E-03 
9.99E-03 
3.19E-04 
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IGF2BP3 
LOC158863 
LIPN 
LOC653056 
LOC100132217 
A_19_P00322866 
KBTBD7 
A_19_P00315808 
UPB1 
A_19_P00320417 
MEGF9 
LOC253981 
PRO2852 
MAP4K4 
MST150 
APP 
LOC100130360 
AF130850 
THC2539584 
A_19_P00813409 
RAB3IP 
ENST00000402522 
BQ945477 
SEPX1 
ANXA1 
LOC100132217 
A_19_P00324174 
EVI2B 
TACC3 
ZNF516 
RTN3 
DEXI 
CMTM1 
BC045716 
TALDO1 
A_19_P00322932 
COLQ 
A_19_P00316992 
DGKD 
SOD2 
LOC100131190 
DAB2IP 
A_19_P00813109 
A_19_P00321324 
A_19_P00802257 
LOC731275 
LOC401357 
A_23_P19987 
A_33_P3576797 
A_33_P3323939 
A_33_P3256095 
A_33_P3343206 
A_19_P00322866 
A_23_P25605 
A_19_P00315808 
A_23_P120822 
A_19_P00320417 
A_32_P129894 
A_32_P116206 
A_33_P3538279 
A_23_P90804 
A_23_P414273 
A_33_P3296479 
A_32_P62211 
A_33_P3499046 
A_33_P3392677 
A_19_P00813409 
A_23_P128174 
A_33_P3370812 
A_33_P3213526 
A_23_P129486 
A_23_P94501 
A_33_P3300843 
A_19_P00324174 
A_23_P66694 
A_23_P212844 
A_33_P3225690 
A_23_P76684 
A_24_P144377 
A_23_P106661 
A_32_P191895 
A_32_P18258 
A_19_P00322932 
A_23_P212126 
A_19_P00316992 
A_23_P210253 
A_23_P134176 
A_33_P3278200 
A_23_P123848 
A_19_P00813109 
A_19_P00321324 
A_19_P00802257 
A_33_P3232624 
A_33_P3365985 
10643 
158863 
643418 
 
100288292 
 
84078 
 
51733 
 
1955 
768211 
114224 
9448 
85027 
351 
 
 
 
 
117177 
23216 
 
51734 
301 
401357 
 
2124 
10460 
9658 
10313 
28955 
113540 
100129960 
6888 
 
8292 
 
8527 
6648 
4600 
153090 
 
 
 
100288069 
401357 
2.155 
2.154 
2.154 
2.153 
2.144 
2.142 
2.141 
2.139 
2.133 
2.132 
2.132 
2.128 
2.125 
2.124 
2.123 
2.123 
2.121 
2.121 
2.118 
2.115 
2.110 
2.110 
2.107 
2.099 
2.096 
2.094 
2.080 
2.076 
2.074 
2.074 
2.056 
2.053 
2.051 
2.043 
2.037 
2.033 
2.028 
2.027 
2.027 
2.025 
2.024 
2.016 
2.010 
2.009 
2.008 
2.008 
2.001 
2.19E-03 
3.48E-03 
6.42E-03 
5.46E-04 
1.41E-05 
6.89E-04 
1.14E-03 
7.10E-08 
6.69E-03 
9.64E-03 
2.42E-03 
4.59E-04 
6.96E-04 
2.24E-03 
8.24E-04 
1.74E-05 
3.11E-03 
1.84E-03 
1.45E-04 
6.93E-05 
1.25E-03 
2.23E-03 
3.04E-03 
5.71E-04 
9.90E-03 
4.16E-05 
8.12E-03 
1.77E-05 
1.71E-04 
1.15E-03 
9.69E-08 
3.36E-03 
7.82E-03 
3.05E-03 
7.87E-05 
6.65E-04 
9.96E-03 
5.05E-04 
1.11E-04 
2.04E-04 
1.41E-07 
2.06E-04 
1.35E-03 
2.23E-05 
5.52E-03 
1.03E-03 
3.76E-05 
 Appendix 
 
97 
EPM2AIP1 
DGCR2 
 
A_24_P627984 
A_24_P125881 
 
9852 
9993 
 
2.000 
2.000 
 
4.89E-03 
1.92E-05 
 
Table 4 Agilent reporters with an at least two-fold downregulation in BDCA1+CD14+ pro-iDCs relative to 
CD14+CD16- monocytes (Tukey test p-value ≤ 0.05). 
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